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ABSTRACT
The Role of Oxidative Stress and Signal Transduction in Chemotherapy- Mediated
Cognitive Impairment in the Menopause Rat Model
By Ciara Bagnall-Moreau
Advisor: Prof. Karen Hubbard
Systemic chemotherapy treatment is associated with long-term cognitive impairment in
breast cancer survivors. While many studies have established the forms of cognition and
corresponding regions in the brain most affected, very little is revealed about the potential
molecular mechanisms that mediate these changes. The effects of systemic treatment on the brain
is likely attributed to many different mechanisms including oxidative stress and immune
dysregulation. Earlier studies from our lab have investigated the effects of the chemotherapy
cocktail doxorubicin and cyclophosphamide (AC Chemotherapy) in an ovariectomized
menopause animal model of ‘chemo brain’ (Salas-Ramirez et al., 2015). We observed that
animals injected with these drugs over a period of three weeks demonstrate deficits in some
forms of hippocampal- mediated memory which correlates with enhanced basal signaling
activity and altered levels synaptic protein expression in the brain. Considering the integral role
of BDNF (brain derived neurotrophic factor) on several processes in the CNS and the
relationship between the levels of the neurotrophin and cognitive performance, we evaluated the
expression of the ligand and its cognate receptor TrkB. Although the levels of BDNF were
unaffected after chemotherapy in the hippocampus and prefrontal cortex (PFc), evidence from
these studies indicate that systemic treatment is associated with the differential activation and
expression of the TrkB receptor isoforms in the two brain regions.
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The mRNA and protein product expression of a panel of immediate early genes
(arc/arg3.1, bdnf, cfos, cjun, creb, homer1a) were also evaluated in the brain. These IEGs have
been documented to have important roles in learning and memory, survival, and the cellular
stress response. AC chemotherapy led to altered phosphorylation and expression of several IEG
proteins in the brain relative to saline controls. There is growing evidence that the effects of
chemotherapy on the CNS may be due in part to inflammation and oxidative stress. We
addressed these hypotheses by examining whether the levels of pro-inflammatory cytokines and
oxidative stress responsive gene markers were altered in the CNS of rats treated with systemic
AC chemotherapy. Ultimately our results indicate that an induction of inflammation and
increased MAPK signaling is accompanied by oxidative damage to nucleic acids, suggesting that
these effects could be linked to the chemotherapy-associated cognitive changes.
The role of oxidative stress and altered intracellular signaling is also addressed in an in
vitro cellular model of doxorubicin-induced neurotoxicity using primary hippocampal neurons.
The results of these studies indicate that doxorubicin induces caspase 3 -dependent apoptosis and
these neurotoxic effects of doxorubicin are associated with the generation of ROS and oxidative
damage. Furthermore, we present results that doxorubicin impairs BDNF-mediated signaling to
the translational machinery and the subsequent induction of the plasticity associated protein
arc/arg3.1, an effect mediated by neuronal oxidative status. All together the results presented in
this dissertation provide strong evidence that the effects AC chemotherapy, and in particular
doxorubicin, is associated with oxidative damage and a global stress response that may underlie
the adverse alterations on the molecular signature of the brain.
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CHAPTER 1
Introduction
1.1 Chemotherapy-related Cognitive Impairment
Systemic chemotherapy treatment is associated with cognitive deficits in some non –CNS
cancer survivors. Despite the efficacy of treatment on improving survival in patients, these
methods often lead to long term complications that impact the quality of life. The prevalence of
Chemotherapy-related Cognitive Impairment (CRCI) ranges from 17%- 75% of patients during
treatment, although a subset of individuals (35%, Koppelmans et al., 2012) experience deficits
that persist for 5-10 years following treatment (de Ruiter et al., 2011). In the United States alone
there are 15.5 million cancer survivors (ACS, 2018), which suggests that millions will likely face
long- term cognitive difficulties stemming from cancer and the related treatments.
There is evidence that patients who receive chemotherapy exhibit more severe cognitive
complications than patients who only receive surgery or localized treatment such as radiotherapy
(Janelsins et al., 2011). Cancer patients undergoing treatment that self-report cognitive problems
often complain of issues relating to concentration, multitasking and memory. Therefore, a
primary concern is evaluating whether these treatment strategies significantly compromise the
patient’s long-term quality of life. A meta-analysis of the research conducted on cancer
therapies and cognition demonstrate the challenge of assessing the impairment in patients
(Hodgson et al., 2013). The earlier cross- sectional studies highlight the wide variation in the
duration, severity of treatment effects and cognitive domains associated with the impairment
(Ono et al 2015). There are methodological discrepancies relating to the type of
neuropsychological tests issued and the criterion used for the determination of the cognitive
impairment is also highly varied in these assessments. A majority of the longitudinal studies
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which include important baseline or pretreatment measures have been conducted using breast
cancer patients although several studies are being applied to other cancers and lymphomas
(Deprez et al., 2012, 2014; Ahles et al., 2015; Wouters et al., 2016).
From these ongoing studies, it has become evident that the phenomenon of this cognitive
impairment is multifactorial. The finding that only a subset of patients manifest these persistent
changes suggests that other risk factors are likely implicated in the development of these
neurocognitive problems. Furthermore, in addition to the class of chemotherapeutic agents used
for treatment and other therapeutic strategies employed in combination, there are other patient
comorbidities that exist prior to treatment that contribute to the overall outcome. These
contributing factors include genetic factors, IQ or educational level, psychosocial factors,
environmental factors and lifestyle, and notably the age of the patient (Moore et al., 2014).

1.2 The Etiology of CRCI
Several biological and psychosocial mechanisms have been proposed as contributors to
the deficits following cancer/chemotherapy treatment (Ahles and Saykin, 2007). A majority of
the evidence of the neural basis of CRCI derive from clinical neuroimaging studies (Kaiser et al.,
2014; Scherling and Smith 2013). There are several functional and structural neuroimaging tools
employed to examine the volume, metabolic processes and activity of specific brain domains. It
has been observed from the anatomical MRI (magnetic resonance imaging) studies that
chemotherapy/cancer associated effects on the brain include structural changes such as reduced
gray matter volume and density (Conroy et al., 2013; de Ruiter et al., 2012; McDonald et al.,
2010). fMRI (functional magnetic Resonance Imaging) have revealed post- treatment differences
in regional brain activation during specific executive and memory tasks (Saykin et al., 2013;

2

Lopez Zunini et al., 2012; McDonald et al., 2012). Other imaging techniques including diffusion
tensor imaging have also indicated microstructural alterations in white matter tracts and volume
post- treatment (Deprez et al., 2013). Interesting findings are revealed from these studies,
demonstrating that various regions of the brain are affected and surprisingly are not always
consistent with the patient –reported cognitive complaints or the domains sensitive to
performance on neuropsychological tests (Biglia et al., 2012). In combination with
neuropsychological tests, neuroimaging is a powerful tool that is revealing the complexity of the
condition and has greatly aided in the overall assessment of the various factors that are
associated with the adverse effects of cancer and/or treatment on brain structure and activity.
Several candidate mechanisms have been hypothesized to contribute to CRCI although
there is a need for more studies to address the role these various factors play in the condition
(Ahles and Saykin, 2007; Wang et al., 2015). The evidence clearly shows that there is a
neurobiological basis for these cognitive changes although specific pathways involved are not
very well defined (Seigers and Fardell, 2011; Kaiser et al., 2014). It is important to note that
chemotherapy is considered a risk factor for the impairment and the extent of these effects are
influenced by the regimen of chemotherapy and the biological mode of action from these
compounds (Janelsins et al., 2011). Indirect and direct neurotoxic effects have been
demonstrated with several breast cancer therapies including cisplatin, fluorouracil,
cyclophosphamide and doxorubicin although there is insufficient information that indicates
which of these compounds pose the highest cognitive risk. The efficacy of anthracycline based
regimens in the treatment of breast cancer has been established in meta- analyses and several
large cohort trials (Gianni et al., 2009). The inclusion of anthracyclines, such as doxorubicin, in
combination with other drugs have been proven to reduce disease progression and improve
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patient outcome (Greene et al., 2015) Although the precise mode of action varies depending on
the type of anthracycline, generally drugs among this class can interact with topoisomerase and
intercalates between DNA base pairs leading to double strand breaks (Yang et al., 2015).
Furthermore, anthracyclines exhibit a redox cycling profile that generates robust levels of free
radicals and reactive oxygen species, a mechanism associated with cardiotoxicity and cardiac
complications (Stěrba et al., 2013). Several clinical studies have demonstrated alterations in
brain functionality and cognitive impairment in breast cancer patients that were treated singularly
with anthracyclines or in combination with other drugs (Mills et al., 2008; Janelsins et al., 2012;
Mcdonald et al., 2012). A recent study found that patients receiving anthracycline- based
treatment exhibited lower verbal memory and significantly lower default mode brain network
connectivity compared to healthy controls and patients who received non- anthracycline
regimens (Kesler and Blayney, 2016). Therefore, anthracyclines such as doxorubicin may carry
an increased risk for cognitive dysfunction and neurotoxicity.

1.3 Genetic Susceptibility: Brain derived Neurotrophic Factor
Growing evidence suggests that the levels of brain derived neurotrophic factor (BDNF)
may be implicated in the development of cognitive dysfunction following cancer treatment.
BDNF is widely distributed throughout the CNS although higher levels can be detected in the
cerebral cortex, hippocampus, hypothalamus, basal forebrain; striatum and cerebellum (Murer et
al., 2001). The biological effects of the neurotrophin are exerted the actions of BDNF on the high
affinity Tropomyosin receptor kinase B (TrkB) receptor to regulate cellular activities including
survival, differentiation and growth. Moreover, BDNF has an integral role in synaptogenesis and

4

synaptic plasticity, through modulatory effects on neurotransmitter release and long-term
potentiation (LTP) (Minichiello, 2009).
Generally, BDNF has been extensively studied for its role in normal cognitive aging and
the pathogenesis of several neurodegenerative disorders (Shimada et al., 2014; Liu et al., 2015;
Xie et al., 2017). A majority of the human clinical studies examine the levels of circulating
BDNF although it is not clear if these peripheral levels reflect trends in the CNS (Klein et al.,
2011). It has however been suggested that the plasma levels of the neurotophin may serve as a
candidate biomarker and predictor of cognitive outcomes across several conditions (Fernandes et
al., 2015). One recent longitudinal study examined the relationship between plasma BDNF
levels and self- perceived impairment in early stage breast cancer patients using Functional
Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) measures. Significantly lower
BDNF levels were measured in patients post-chemotherapy than controls and these changes were
associated with self-perceived cognitive deficits (Ng et al., 2017). There are several limitations to
this pilot study, most notably the lack of objective criterion for the cognitive assessment.
BDNF gene polymorphisms are associated with normal cognitive functioning, anxietyrelated behaviors and other neuropsychiatric conditions, and emerging evidence suggests that
these single nucleotide polymorphisms (SNPs) may predispose some individuals to
neurodegenerative disorders in non-cancer populations (Gratacias et al., 2007; Bialecka et al.,
2014). In particular the Val66Met (valine to methionine substitution at codon 66, rs6265) is a
common variant linked to a reduction in activity-dependent secretion of BDNF and is associated
with poor episodic memory and lower hippocampal activation/volume (Egan et al., 2003). A
few cross-sectional cohort studies have also suggested that BDNF -Val66Met variant may be
associated with susceptibility to chemotherapy related cognitive impairment. In one study on
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early breast cancer patients, the BDNF -Val66Met polymorphism was found to be strongly
associated with C-reactive protein (CRP), an inflammatory marker linked to depressive
symptoms (Dooley et al., 2016). Another study demonstrated contrasting findings, the authors
concluded that the BDNF -Val66Met polymorphism is potentially protective against
chemotherapy-associated cognitive impairment. They observed that carriers of the BDNF Met
allele were less likely to experience impairment in the verbal fluency and multitasking ability
domains of self-perceived cognitive functioning (Ng et al., 2016).

1.4 Brain Metabolism and Structural changes
Functional neuroimaging studies in breast cancer patients treated with chemotherapy
have suggested that cognitive impairment, particularly reduced executive function domains,
correlates with regionally altered brain function. Decreased activity in the frontal cortex during
working memory processing (Kesler et al., 2011), as well as reduced frontal, temporal, parietal,
and cerebellar cortical volume have been observed in cancer patients receiving adjuvant
chemotherapy (Inagaki et al 2007; Mcdonald et al., 2010; de Reuiter et al., 2011; Wang et al.,
2016). However other studies have demonstrated hyperactivation or increased connectivity in
chemotherapy-treated survivors during cognitive tasks (Mcdonald et al., 2012; Menning et al.,
2017). It has been suggested that this increased activity serves as ‘neural compensation’ in some
patients where the specific region of the brain would be required to work harder to counteract the
damage inflicted on brain networks due to the chemotherapy to preserve performance during
active tasks (Janelsins et al., 2014) .
Further evidence is demonstrated from PET/CT (Positron emission tomography–
computed tomography), which is utilized for anatomic localization of metabolic changes
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(Clintolo et al., 2013). Therefore, this powerful imaging technique has a better contrast
resolution of tissue densities which can then detect metabolic uptake in different brain structures.
Recent studies using the radiolabeled glucose molecule, 18-fluorodeoxyglucose (FDG) in PET
imaging, a common technique often employed in Alzheimer’s diagnosis, have demonstrated
metabolic changes in specific brain regions at baseline and post-chemotherapy (Silverman et al.,
2007). Future studies will be necessary to delineate whether these metabolic changes detected
with imaging techniques correlate with neuropsychological measures and are truly linked to
cognitive changes using objective criteria.
1.5 Inflammation
Cytokines are small secreted proteins that have essential roles in normal CNS
homeostasis but it is well documented across various cancers that the circulating levels of proinflammatory cytokines are greatly enhanced. Inflammation is linked to a generalized ‘sickness
behavior” which include fatigue, loss of appetite, depression, and other psychological
manifestations (Dantzer and Kelley, 2007). Therefore, it has been suggested that increased
cytokine production and systemic inflammation is a strong candidate mechanism in the etiology
of cognitive impairment after chemotherapy administration (Figure 1.1). The types and
robustness of cytokine production is clearly dependent on the state of disease progression and the
treatments used. For example, patients receiving specific chemotherapy agents such as
anthracyclines in the regimen exhibit increased circulating levels of INF-α, IL-1β, IL-6, IL-8, IL10, and MCP-1. Clinical studies have also found correlations between cognitive dysfunction and
the increases of specific cytokines. For example, the peripheral levels of the cytokines TNF-α,
IL-6, IL-8, IL-10, and MCP-1 were higher in patients with cognitive dysfunction who exhibited
self- reported complaints or were assessed with neuroimaging and cognitive testing (Janelsins et
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al., 2012; Bower et al., 2013; Pomykala et al., 2013) .Although there is strong evidence for the
role of inflammation in the cognitive deficits associated with chemotherapy, it is not entirely
clear how these inflammatory molecules exert their effects on the CNS. It has been suggested
and that peripheral circulating cytokines could impact the levels of CNS cytokines either directly
– through transport-system mediated infiltration across the blood brain barrier, or indirectly,
through leaky regions of the blood brain barrier BBB around the CVO (circumventricular
organs) (Yarlagadda et al 2009). There have only been a few studies conducted to test the
relationship of specific cytokines on CRCI. In this animal model, the authors found that despite
the limited transport of Adriamycin (doxorubicin) across the BBB, both the peripheral and CNS
levels of TNFa were detected in the treated animals at significantly increased levels (Tangpong
et al., 2006). Further studies will be required to clarify the role of the cytokines and other
immune molecules on cancer and treatment -related cognitive impairment.

Figure 1.1: Chemotherapy-induced cognitive dysfunction is associated with
inflammation. Adapted from Wang et al., 2015
8

1.6 Hormonal Status
Chemotherapy is a risk factor for cognitive impairment in breast cancer survivors, but it
has been suggested that menopausal status may also contribute to the negative effects of cancer
treatment on brain function. Depending on the molecular signature of the breast cancer, patients
are often prescribed aromatase inhibitors or hormonal therapies such as tamoxifen that function
to perturb hormone production and activity. Other classes of non-hormonal adjuvant
chemotherapies are also documented to induce premature menopause and the onset of related
symptoms in breast cancer patients that were pre-menopausal prior to treatment (Okanami et al.,
2011). The hormone estrogen is not only recognized for a role in reproductive health but also as
a significant neuroprotectant and neuromodulator in the brain (Markou et al., 2005; McEwen,
2012; Luine, 2014). The presence and abundance of estrogen receptors in specific areas of the
brain including the hippocampus supports a key role for the hormone in cognition. There are
numerous studies that have examined cognitive function in menopausal women or after surgical
ovarian loss and generally the findings from these studies show a decline in memory and
cognitive function (Greendale et at., 2011). Moreover, mild cognitive deficits and Alzheimer’s
disease risk were found to be partially reversed by estrogen replacement therapy (ERT) if the
therapy is initiated immediately following ovarian hormone loss (Maki and Henderson, 2012;
Sherwin, 2009). Thus, it is plausible that reduced estrogen may interact synergistically with
chemotherapy or exhibit independent effects on memory and cognition.
1.7 Aging
As the aged population (>65 years) grows at an unprecedented rate, so will the incidences
of cancer diagnoses within this population. Aging is considered a risk factor for cognitive
impairment. The incidence of mild cognitive impairment (MCI) and dementia is high among
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older adults (Plassman et al., 2007; Langa et al., 2017). Due to prevalence of preexisting factors
and the cognitive deficits that manifest in the aging population prior to cancer diagnosis, there
exists a challenge to isolate the role that a diagnosis and cancer treatment regimen may play in
the cognitive impairment. While a majority of studies have focused on the relatively short-term
effects of cancer treatment (~one year), it has been suggested that chemotherapy may be a risk
factor for cognitive impairment and dementia later in life. According to one co-twin study, the
authors evaluated the cognitive status of older cancer survivors and their cancer-free twins. It
was found that the cancer survivors were more likely than their co-twins to have cognitive
dysfunction and also twice as likely to be diagnosed with dementia, but these differences did not
reach statistical significance (Heflin et al., 2005). An earlier study sought to determine the
prevalence of dementia in cancer survivors and found significant differences at baseline between
individuals who received and did not receive chemotherapy (Heck et al., 2008). Dementia was
more common in women who had not had chemotherapy suggesting the possibility of severe
cognitive changes associated with chemotherapy later in life. There is however conflicting
evidence for this relationship. Other studies failed to find an association between cancer
therapies and risk of dementia which requires the need for additional studies to examine the
incidence of cognitive dysfunction in elderly populations of cancer survivors (Baxter et al., 2009;
Raji et al., 2009).
1.8 The Role of Oxidative Stress in CRCI
As discussed previously the cognitive impairment in cancer patients is influenced by
numerous factors. Several of the antineoplastic agents used in cancer treatment induce oxidative
stress. Either as a primary mechanism or synergistically as an effect generated by interactions
with cellular organelles, the generation of free radicals may also promote the efficacy of
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chemotherapy to target cancerous cells (Chen et al., 2007). Evidence from the Butterfield lab
have demonstrated that doxorubicin, an anthracycline drug commonly used in the treatment of
breast cancer is associated with lipid peroxidation of plasma proteins, including ApoA-I that
initiates a TNFa -mediated neurotoxicity in the brain of treated rats (Aluise et al., 2011).
Oxidative stress results from an imbalance between the production and scavenging of
reactive oxygen or nitrogen species (ROS or RNS). In the brain, the excessive generation of ROS
is implicated in acute conditions such as traumatic brain injury and ischemia, as well as in
chronic neurodegenerative disorders, such as Alzheimer’s disease and Parkinson’s disease. The
free radical theory as proposed by Harman postulates that the accumulation of macromolecular
damage from oxygen free radicals (and non-free radical ROS) may drive the functional
alterations associated with aging (Harman, 1956). Neurons are particularly susceptible to the
effects of ROS due to a high ratio of brain to body oxygen consumption and a relatively low
antioxidant capacity in comparison with other tissues (Watson et al., 2006). Therefore, the brain
is vulnerable to oxidative stress that accompany aging. The inability of the cellular antioxidant
mechanisms to effectively detoxify ROS leads to the chemical modification of essential proteins,
lipids and nucleic acids. Such modifications can result in structural changes and a loss of
function of these molecules which impose damaging effects on the brain. A major source of ROS
production arises from the mitochondria. During aerobic respiration, molecular oxygen is the
terminal electron acceptor and is completely reduced to water. However, under normal
physiological conditions some electrons may still leak from the mitochondrial respiratory chain
accounting for about 2% of the O2 that is partially reduced and converted to highly reactive
superoxide anion radicals. Furthermore, this rate of ROS production from mitochondria is
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enhanced in the aged brain and in a variety of pathological conditions (Serrano and Klann, 2004;
Kishida and Klann, 2007).
1.9 Oxidative Stress and Cognition
Oxidative stress contributes to the age-related decline in cognitive function. In contrast
with pathological conditions such as in Alzheimer's disease, normal brain aging is not associated
with significant cell loss or gross morphological changes (Burke and Barnes, 2006). Instead, it is
suggested that subtle and selective alterations in the functional connectivity of synapses are
responsible for changes in cognition (Burke and Barnes, 2010). Impairments in synaptic
plasticity underlie deficits in learning and memory. It is not clear whether this process is targeted
by oxidative stress during aging. Substantial evidence demonstrates that oxidative stress is
increased in the aged brain (Floyd and Hensley, 2002). The long term dietary supplementation of
N-acetyl-L-cysteine (L-NAC) was shown to attenuate oxidative damage and rescue the age related impairment in NMDAR -dependent LTP (Haxaire et al., 2012). Aged transgenic mice
overexpressing the gene for the antioxidant enzyme superoxide dismutase (SOD) show enhanced
performance on spatial memory tasks than age-matched wild-type mice (Kamsler et al., 2007).
Interestingly, the attenuation of this memory decline is specific to advanced age. In younger
animals, extracellular superoxide dismutase (EC-SOD) overexpression impairs rather than
improves contextual learning supporting a physiological role for ROS in synaptic plasticity
(Levin, 2005; Hu et al., 2007). Elevated levels of ROS are associated with a poorer outcome on
cognitive tests of short term memory in aged mice (Ali et al., 2011). It is suggested that synaptic
superoxide derived from NADPH oxidase (NOX) rather than from mitochondria may be related
to these age -related cognitive deficits (Dugan et al., 2009). Extra-mitochondrial sources of ROS
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that can potentially contribute to brain function are produced from enzymatic reactions involving
monoamine oxidase, cyclooxygenase, and the nitric oxide synthases (Kishida and Klann, 2007).

Figure 1.2: Methods for the determination of oxidative stress.
Adapted from Katakwar et al., 2016

1.10 Biomarkers of oxidative Stress
Oxidative stress is a common mediator in pathobiology of risk factors for cancer-related
mediated cognitive impairment. Excessive free radical and ROS production from chemotherapy
and/or radiation can damage macromolecules, including nucleic acids, lipids and proteins
(Holmstrom and Finkel, 2014). Apparent targets of oxidation include DNA, lipids and proteins.
There are several challenges to quantifying the extent of oxidative stress in vitro and in vivo due
to the relatively short half-life of free radicals and the detoxifying systems that scavenge them.
13

Several direct and indirect methodologies exist for the evaluation of oxidative stress as outlined
in Figure 1.2. However, several biomarkers exist as biological molecules that are modified by
interactions with free radicals. Alternatively, the oxidative stress index is assessed by the total
antioxidant capacity, a component of cellular defenses that is modulated in response to the levels
of ROS in the microenvironment.
1.11 Lipid Peroxidation
Lipid peroxidation occurs when there is oxidative damage to lipids, phospholipids in
cellular membranes, lipoproteins, and other lipid containing molecules. Lipid peroxidation is a
prominent form of oxidative damage in the CNS due to the high concentration of
polyunsaturated fatty acids relative to other organ systems (Shichiri, 2014). The products of lipid
peroxidation are reactive aldehydes, such as malondialdehyde (MDA) and 4-hydroxynonenal
(HNE), which can be quantified by various means as an indirect index of oxidative stress. These
end products impair normal cellular function, and has been shown to exhibit neurotoxic
properties in vitro (Mark et al., 1997). Lipid peroxidation has also been implicated in diabetes,
atherochlerosis, cancer and higher levels of the end products HNE and MDA correlate with
advanced age and neurodegenerative disease (Zarkovic, 2003).
1.12 Protein oxidation
Protein oxidation is a common target oxidative stress and has been documented across
various disease states. Protein tyrosine nitration is a common modification mediated by reactive
nitrogen species such as peroxynitrite Nitration of tyrosine residues in enzymes may inhibit
their normal catalytic activity and has been demonstrated to play a pathophysiological role in
cardiovascular disease (Peluffo and Radi, 2007). Protein carbonylation is another major hallmark
of oxidative damage. High levels of carbonyl groups have also been observed in several diseases
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including Alzheimer’s disease. Interestingly, the targets of protein carbonylation include classes
of proteins that play an important role in metabolism and mitochondrial function (Bizzozero,
2009; Brigitte et al., 2013).
1.13 Nucleic Acids
Nucleic acids are susceptible to oxidative damage by ROS, RNS and lipid peroxidation.
These free radicals may directly attack either the sugar, phosphate or induce lesions in purine and
pyrimidine bases of the nucleic acids leading to impairments in replication or translation.
Ultimately these adverse effects lead to mutations and altered gene expression that compromise
normal cell physiology.
1.13.1 DNA
Due to its low redox potential, guanine is the most susceptible DNA base to oxidative
damage (Kino et al 2017). The two most common modifications include 8-oxo-7, 8dihydroguanine (8-oxoGua) and 2, 6-diamino-4-hydroxy-5-formamidopyrimidine (FapyGua)
which occur when a hydroxyl radical is added to the C8 position of a guanine ring. This produces
an 8-hydroxy-7, 8-dihydroguanyl radical, which is then either oxidized to 8-oxoGua or reduced
to result in the ring-opened FapyGua. Due to the stability of 8-oxoGua, it is often used as a
biomarker for oxidative damage to nucleic acids. Moreover, 8-oxoGua is a mutagenic DNA
lesion that could promote mispair with adenine during DNA replication to generate GC to TA
transversion mutations (Shibutani et al., 1991; Kino et al., 2017).
When high levels of DNA lesions exceed the capacity for cellular repair, apoptosis can be
triggered. An important regulator of the cellular response to ROS-induced DNA damage is the
tumor suppressor protein p53 (Achanta and Huang, 2004). High levels of DNA damage induce
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the activation of p53 which functions as a transcription factor that regulates the expression of
target genes involved in DNA repair, cell cycle arrest, senescence, and apoptosis.
Chemotherapeutic agents target rapidly dividing cancer cells either directly or indirectly by
inducing DNA damage. Furthermore, the induction of oxidative stress by these cytostatic drugs
have been documented with cyclophosphamide, cisplatin, methotrexate, and doxorubicin (Oboh
and Ogunruku, 2010; Joshi et al., 2005; Montilla et al., 1997; Öz and Ilhan, 2006; Rajamani et
al., 2006; Uzar et al., 2006).
In particular, the anthracycline class of drugs which include doxorubicin have high
oxidative potential and can generate high levels of ROS. Doxorubicin (Dox), possesses a sugar
moiety attached to a tetracycline ring that contains a quinone structure that undergoes redoxcycling in the presence of oxygen to form superoxide anion. Thus, dox is one of the most studied
agents and its oxidative damage to genomic and mitochondrial DNA by the reactive
intermediates have implicated it in the involvement of a number of pathological conditions
(Capetta, 2017). It is important to note that oxidative damage to DNA can induce a number of
mutagenic lesions that also lead to the progression of cancer (Waris and Ahsan, 2006).
1.13.2 RNA
Although most of the focus of oxidative damage has been placed on DNA, accumulating
evidence has shown that RNA is more susceptible to oxidative damage by ROS or RNS. It has
been suggested the incidence of this damage to free radicals is likely due to the several reasons.
RNA is mainly a single-stranded molecule and has limited association with proteins, therefore it
is likely that RNA is more accessible to ROS. Furthermore, due to the extensive distribution of
RNA in several subcellular compartments and the relatively close proximity of cytoplasmic RNA
near sites of ROS generation around mitochondria, RNA is particularly vulnerable to oxidative
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damage (Nunomura et al., 2006; Shan et al., 2007). Finally, although several active repair
mechanisms exist for DNA, processes implicated in the repair of oxidatively-damaged RNA
have not been clearly defined. (Wurtmann and Wolin, 2009). Similar to DNA, the oxidation of
RNA can also result in abasic sites, strand breaks, and modified nucleobases and sugar groups.
Perhaps due to the overall abundance of RNA, the levels of RNA oxidation levels are also much
higher than DNA oxidation levels. 8-Hydroxyguanosine (8-OHG) is the most common
modification found in the RNA and is typically assessed as a biomarker for oxidative damage.
Oxidative damage can impact RNA function although there is limited information about the
effects of this modification. Studies conducted in vitro have demonstrated that oxidized RNA is
associated with a decline in protein translation and a higher level of truncated proteins (Figure
1.3; Shan et al., 2003, 2007; Tanaka et al., 2007)).Growing evidence have implicated higher
levels of RNA oxidation in numerous age-related conditions including Alzheimer’s disease,
atherosclerosis , and Parkinson’s disease( (Nunomura et al., 1999; Zhang et al., 1999; Abe et al.,
2002; Kikuchi et al., 2002; Martinet et al., 2004; Weidner et al., 2011).It will be of considerable
interest to examine the potential contributions of RNA oxidation to the etiology of
chemotherapy induced cognitive impairment.
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Consequences of oxidative damage to
RNA species

Figure 1.3: Consequences
of oxidative damage to RNA.
Simms and Zaher 2016
Adapted from Simms and Zaher, 2016

1.14 Signal transduction and Oxidative Stress
Reactive oxygen species (ROS) has an essential role as mediators of normal and
pathological signal transduction pathways. Growing evidence has demonstrated significant
increases in intracellular ROS immediately following stimulation by ligand-receptor interactions
of growth factors or inflammatory cytokines to GPCRs (G-protein coupled receptors), receptor
tyrosine kinases (RTKs), Receptor serine/threonine kinases (RS/TK), as well as ion-channel
linked receptors (Thannickal and Fanburg, 2000). Likewise, the targets of oxidative stress and
ROS may also be receptor kinases and regulatory phosphatases themselves. For example,
exogenously applied H O has been demonstrated to induce the phosphorylation and subsequent
2

2

activation of tyrosine receptor kinases (Gamou and Shimizu, 1995). Other mechanisms of
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receptor modifications were found to be related to ROS-mediated inhibition of membrane-bound
protein tyrosine phosphatases that function in the dephosphorylation and inactivation of RTKs
(Knebel et al., 1996).
Multiple downstream signaling pathways are affected by ROS and the activation of
protein kinases is critical in sensing oxidative stress and transducing signals to initiate a cellular
response.
1.14.1 The MAPKs
Mitogen-activated protein kinases (MAPKs) comprise a large family of protein kinases
that include the extracellular signal regulated kinases - ERK1/ERK2 (p44MAPK /p42MAPK),
the c-Jun N-terminal kinases (JNKs) and p38 MAPKs. These signaling molecules play an
important role in relaying extracellular signals from the cellular membrane to the
nucleus through a cascade of phosphorylation events. There has been significant interest in the
redox regulation of these pathways due to the role of MAPK signaling in the mediation of both
mitogen- and stress-activated signals. Furthermore, the MAPK signaling pathways have been
implicated in the pathogenesis of many neurodegenerative diseases and cancers.
1.14.1.1 ERK1/2 MAPK
The ERK1/2 signaling pathway is a prototype of the kinase cascades since it was the first
MAPK pathway to be elucidated. Growth factor receptors are commonly activated by ligandinduced dimerization that induces the autophosphorylation and activation of the receptor tyrosine
kinases RTKs. These modifications lead to the induction of the Ras-GTPase which further
activates the MAP3K/ Raf. Raf is responsible for transmitting signals to MAP/ERK Kinase
(MEK) which activates ERK 1 and ERK2 (ERK1/2) through phosphorylating regulatory
threonine and tyrosine residues within the activation loop of the ERK1/2 protein. ERK 1/2 is
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then capable of phosphorylating various MAPKAPK components including RSKs, MNKs and
MSKs, as well as many other substrates which that have extensive subcellular localization in
various organelles, the cytoplasm, and nucleus (Yao Z and Seger, 2009).
1.14.1.2 JNK/SAPK
The JNK cascade was initially identified as a mediator of stressful stimuli and a direct
regulator of the transcription factor c-Jun. Several cytokines, transforming agents, growth factors
and biosynthesis inhibitors have been demonstrated to activate this pathway which is also named
the stress-activated protein kinase pathway (SAPK) (Johnson, 2007). In response to stimuli,
several upstream kinase proteins couple signals to JNK. Initially the small GTPases CDC42 or
Rac1 transmit signals to the MAP3K level kinases. In this diverse class of kinases, the MAP3Ks
can activate MAP2Ks, MKK4 or MKK7, which can then activate the JNK proteins (JNK1-3) by
phosphorylating the threonine and tyrosine residues within the activation loop of the respective
JNK. (Weston and Davis, 2007).
.

The JNK signaling pathway is implicated as a key modulator in ROS/RNS mediated cell

death (Shen and Liu, 2006). Several studies have established a role for JNK signaling in the
mediation of oxidative stress regulation of cellular redox-sensitive proteins. It has been
demonstrated that ROS can oxidize thioredoxin, a negative regulator of the ASK1 (Apoptosis
signal-regulating kinase 1)-JNK/p38 pathway, leading to nuclear translocation of JNK and
apoptosis induction in cells (Matsuzawa and Ichijo, 2008).
1.14.1.3. p38 MAPK
The p38 signaling cascade shares many components with the JNKs, and is primarily
activated in response to stressful stimuli. However, other factors may also induce the signaling
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pathway that implicates the p38 pathway in processes including apoptosis, immune regulation,
cellular senescence, cell growth and survival (Coulthard et al., 2009; Huang et al., 2009;
Maruyama, 2009). Diverse stimuli and other extracellular cues are propagated through receptors
to a number of GTPases which also relay the signal to MAP3K level kinases similar to the
proteins involved in the JNK cascade. The signals are then relayed to the MAP2Ks, including
MKK 3 and MKK6, that can further phosphorylate either of the p38 isoforms (p38 α–δ)
(Cuadrado and Nebreda, 2010). Several ROS species have been shown to activate the p38
cascade. Although specific mechanisms are unclear, it is plausible that oxidative modifications of
MAPK signaling proteins players and the inactivation of the Mitogen-activated protein kinase
phosphatases (MKPs) are implicated in this process (Son et al., 2011).
1.14.2 Oxidative Stress, MAPKs and Gene Regulation
The downstream nuclear targets of many of the MAPKs include transcription factors that
regulate the transcription of a number of immediate early genes (IEG) including c-Fos, other IEG
products from the Fos, Myc, and Jun family (Treisman, 1996). The ERK1/2 cascade has been
shown to induce activation of transcription factors leading to rapid transcription of IEGs on the
order of minutes upon extracellular stimulation (Yang et al., 2003). Several transcription factors
contain several MAPK docking sites and consensus phosphorylation sites in its activation
domain which may contribute to the specificity of the target substrate (Bardwell et al., 2003).
Additionally, the MAPKs have a role in the suppression of gene activity that may be mediated
through the regulation of transcriptional factors, repressors, and the direct interaction with DNA
(Hu et al., 2009).
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In response to oxidative stress, there are numerous signaling molecules that are
implicated in cellular responses including a number of protein kinase families, Ca and other
2+

second messengers (Thannickal and Fanburg, 2000). There still remains several key mechanisms
to be elucidated in the understanding all the players involved in the oxidative stress response and
the specificity of ROS signaling.
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Chapter 2
Chemotherapy -mediated Cognitive Impairment in the Menopausal Model
Rat
Abstract
Chemotherapy is an effective approach for the treatment of several cancers. An increasing
number of studies have suggested that the long-term effects of chemotherapy may be associated
with cognitive dysfunction in some cancer survivors. The effects of systemic treatment on the
brain is likely attributed to many different mechanisms including oxidative stress and immune
dysregulation. We have investigated the effects of the chemotherapy cocktail doxorubicin and
cyclophosphamide (AC Chemotherapy) in an ovariectomized animal model of ‘chemo brain’
(Salas-Ramirez 2015). We have found that animals injected with these drugs over a period of
three weeks demonstrate deficits in spatial memory and tissue analyses show higher activation of
the signaling proteins Akt and ERK/MAPK. Furthermore, the levels of the scaffolding molecule
PSD95, a protein implicated in the synaptic trafficking of receptors and signaling proteins, are
also higher in chemo- treated animals. Gene expression across various regions in the brain is
dynamically altered in response to activity and several mediating factors including
environmental cues. Techniques are often applied to examine the expression of immediate early
gene (IEG) products which are used as markers for the mapping of brain activity in response to
different stimuli. These IEGs are often implicated in the primary response to a variety of signals
and encodes protein products that function as transcription factors and important cellular
regulators. We evaluated the mRNA and protein product expression in the hippocampus and
prefrontal cortex (PFC) of a panel of IEGs documented to have important roles in learning and
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memory, survival, and the cellular stress response. Considering the integral role of BDNF (brain
derived neurotrophic factor) on several processes in the CNS and the relationship between the
levels of the neurotrophin and cognitive performance, we evaluated the expression of the ligand
and its cognate receptor TrkB. There is growing evidence that effects of chemotherapy on the
CNS may be due in part to inflammation and oxidative stress. We addressed these hypotheses by
examining whether the levels of pro-inflammatory cytokines and oxidative stress responsive
gene markers were altered in the CNS of rats treated with systemic AC chemotherapy. We
further evaluated the levels of oxidatively modified nucleic acids in the animals using both
immunohistochemical and northern blotting techniques with a monoclonal antibody against 8hydroxy-guanosine (8OHG) and 8-OHdG lesions.
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2.1 Introduction: Neurobiological Mechanisms of Chemotherapy-related
cognitive dysfunction: Evidence from Animal Studies

Several factors contribute to cognitive impairment experienced by a growing number of
cancer survivors who receive chemotherapy. Although some invaluable insight into the
complexity of the condition is addressed in clinical studies, the interpretation of many of the
findings are often complicated by the presence of comorbidities and other contributory variables
independent of treatment status. Animals studies have greatly expanded the biological
knowledge of CRCI and have facilitated the design of controlled experiments to address the
various candidate mechanisms (Seigers and Fardell, 2011). Evidence from behavioral
assessments as well as molecular and physiological approaches have contributed significantly to
the body of research. A majority of the studies conducted with rodents have established the
domains of cognition that are affected by various chemotherapy treatments and have identified
promising behavioral and pharmacological interventions for reducing the adverse effects of
treatment (Seigers and Fardell, 2011; Seigers et al., 2013). Some of the experimental tools used
in the human clinical research are also being explored in these animal models. A recent study
demonstrated the usefulness of combining behavioral testing with in vivo positron emission
tomography (PET) metabolic imaging (Barry et al., 2018). The authors found decreased
performance on the novel object recognition task was associated with decreased
Fludeoxyglucose (18F) uptake in the prefrontal cortex of rats after doxorubicin treatment.
Overall a growing number of these animal studies have provided evidence for a several of the
proposed mechanisms for the effect of chemotherapy on the brain.
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2.1.1 Impaired neurogenesis and cell survival
Most of the chemotherapeutic drugs used for the treatment of cancer are designed to
perturb cell proliferation therefore it is not surprising to find that some of the cytostatic agents
were associated with the inhibition of neurogenesis in the dentate gyrus region of the
hippocampus. Most of the tools employed to address cell proliferation include metabolic labeling
and immunohistochemical approaches using the nucleotide analog BrdU which is stably
incorporated into actively dividing cells, and a number of antibodies specific to proliferation (Ki67) or cell lineage. A decrease in neurogenesis or overall cell proliferation has been observed in
animals treated with various chemotherapeutic agents: carmustine (Dietrich et al., 2006),
cisplatin (Dietrich et al.,2006) , cyclophosphamide (Yang et al., 2010; Janelsins et al., 2010;
Christie et al.,2012), doxorubicin (Christie et al., 2012; Janelsins et al., 2010), 5-FU (Han et
al.,2008; Mustafa et al., 2008; Janelsins et al., 2010s), MTX (Seigers et al., 2008, 2009; Lyons et
al., 2011; Yang et al., 2012), thiotepa (Mignone and Weber, 2006; Mondie et al., 2010) and
combination, cyclophosphamide + doxorubicin + 5-FU (Rendeiro et al 2016).
Additionally, it was found that while most of the agents tested were found to perturb
proliferation, other compounds may actively target and induce apoptosis in the newly born
neuronal cell populations (Dietrich et al., 2006). In a recent study (Wu et al., 2017),
cyclophosphamide treatment in rats was associated with suppressed adult hippocampal
neurogenesis and abnormalities in the number and structure of dendrites in newborn granule
cells. These results suggest that the development of the dendritic structures in newborn cells in
the hippocampus may be impacted by chemotherapy which may contribute to the negative
effects of treatment on cognitive functioning.
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2.1.2 Inflammatory Mechanisms
Due to the limited transport of many of the cytostatic agents across the blood brain
barrier, the effects of chemotherapy in the brain could be mediated in part through
neuroinflammatory mechanisms. Several animal models have corroborated the clinical studies
showing an increase in the levels of cytokines or inflammatory brain macrophages following
various treatments. An increase in the number of active microglia in the hippocampus and an
impairment in cognitive performance was reported in mice after methotrexate treatment (Seigers
et al., 2009, 2010). The authors however did not find effects on CNS cytokine levels in these
studies. Christie et al., 2012 found that although cyclophosphamide or doxorubicin-treated rats
display significantly impaired performance on various behavioral tasks, activated microglia
(ED1-positive cells) were only found after cyclophosphamide treatment. Aluise et al. (2010,
2011) reported that an intraperitoneal administration of doxorubicin led to elevated TNF-α in the
plasma and brain of mice. Another study found that CMF (cyclophosphamide, methotrexate, and
5-fluorouracil) led to cognitive impairment in rats as assessed by a Y maze and a significant
increase in the levels of proinflammatory molecules IL-1β, TNF-α, and COX-2 although the
levels of the anti-inflammatory cytokine IL-10 decreased (Briones and Woods 2014).
2.1.3 Oxidative Stress
The generation of ROS and oxidative damage caused by chemotherapeutics agents either
directly or indirectly, is one of the underlying mechanisms of the toxicity of anticancer drugs in
the brain (Gaman et al., 2016). Doxorubicin is generally limited from entering the brain, but is
capable of inducing oxidative stress through an elevation of circulating TNF alpha in the blood
plasma. Specifically, it was suggested that doxorubicin leads to the oxidation of plasma proteins
such as APOA1 which mediates TNF alpha production by macrophages (Aluise et al., 2011).
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Therefore peripheral TNF alpha may promote indirect neuronal injury in the CNS by inducing
glial –mediated cytokine upregulation and oxidative stress in the brain (Joshi et al 2005;Aluise
et al 2010) .Alterations in the levels of the brain antioxidant enzymes glutathione peroxidase,
glutathione reductase and glutathione-S-transferase , and an increase in the levels of oxidized
brain proteins were observed in the brain of doxorubicin-treated animals relative to saline
controls (Joshi et al 2010). Additionally, the findings of increased levels of apoptosis markers
along with a decrease in mitochondrial respiration after doxorubicin treatment support a role for
chemotherapy in CNS injury (Tangpong et al., 2006).
Cyclophosphamide is a commonly used alkylating agent demonstrated to induce
oxidative stress in the CNS. The levels of malondialdehyde (MDA), a product of lipid
peroxidation was significantly increased in the brain after exposure (Oboh et al., 2011).
Furthermore, in another study, cyclophosphamide was demonstrated to inhibit the activity of
brain catalase and plasma antioxidant enzymes (Ince et al., 2014). The presence of oxidative
stress and ROS formation has been observed in the brain and/or periphery for a number of
cytostatic agents, including cytarabine (Geller et al., 2001; Koros et al., 2007; Korosand Kitraki,
2009); Carmustine/BCNU (Helal et al 2009); and MTX (Rajamani et al., 2006; Uzar et al.,
2006).
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2.1.4 The Effects of AC Chemotherapy (doxorubicin + cyclophosphamide) and Hormonal
Status in a Rodent Model of CRCI (Salas-Ramirez et al., 2015)
As summarized in the body of animal and clinical research presented in this report, there
is substantial evidence that chemotherapy contributes to both subjective and objective changes in
cognition. In an earlier study from our lab, we evaluated chemotherapy –induced cognitive
dysfunction induced by AC drug combination in tumor-free female Sprague Dawley rats. In this
study, we included ovary-intact and ovariectomized (OVX) animals as a model for
postmenopausal breast cancer survivors. Animals were administered a combination of
cyclophosphamide (40 mg/kg; LKT Laboratories) and doxorubicin (DOX 4mg/kg; LKT
Laboratories) or an equal volume of saline once a week for 3 weeks. Rats were allowed 1 week
to recover before beginning behavioral or molecular assessments.
The results of the behavioral testing demonstrated that AC chemotherapy can impair
cognitive function in rats. Furthermore, this effect is independent of hormonal status as drug
treated intact and OVX animals show similar deficits in hippocampus-mediated behaviors.
The Y Maze spontaneous alternation behavioral test measures working memory and is a
paradigm based on the natural tendency of rodents to explore a novel environment. The
hippocampus is primarily involved in the task, but other areas including the prefrontal cortex,
basal forebrain and septum are also implicated in the circuits that mediate the tested behavior
(Conrad et al., 1996; Lara and Wallis, 2015). Rodents are assessed on their preference to
investigate a new arm of the maze rather than returning to one that was previously visited.
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Figure 2.1: Chemotherapy impairs working
memory. From Salas –Ramirez et al., 2015

We further assessed spatial memory using the Object Placement Memory Task (Vogel-Ciernia
and Wood, 2014). In this paradigm, animals are habituated to an empty training arena, trained
with two objects and then tested with the two objects. The object is moved to a novel location
after an inter-trial delay and the time spent in exploration of the two objects was recorded.
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Figure 2.2: Chemotherapy impairs spatial
memory. From Salas –Ramirez et al., 2015

status.
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In this earlier study, we did not observe any serious health complications in the animals aside
from a slight reduction in body weight and mild alopecia. AC chemo-treated rats did not exhibit
any differences in the behavioral measures of anxiety or visual memory although a decrease in
locomotor activity was noted in chemo-groups (Salas-Ramirez et al., 2015).
We also examined the expression and activation of signaling proteins and molecules implicated
in survival and synaptic plasticity in the hippocampus of a parallel cohort of rats that were not
evaluated behaviorally. Western analysis revealed that the activated forms (phosphorylated
forms) of both Erk1/2 and Akt were significantly increased in chemotherapy-treated OVX rats
but not intact animals (data not shown; Salas-Ramirez et al., 2015). A slight but significant
decrease in Akt activation was however observed in intact rats after AC chemotherapy exposure.
Further the levels of the scaffolding protein PSD95 were significantly increased in treated OVX
female rats compared to OVX controls but no difference was found between the intact groups
(data not shown).

In this study, we also measured the hippocampal
levels of the neurotophin BDNF. We did not find
any differences in BDNF levels between the
control and AC chemo-treated groups. A surprising
finding was an increase in BDNF levels in OVX
rats compared to intact rats (Fig. 2.3) regardless of
treatment.

Figure 2.3: Chemotherapy does not
affect the levels of BDNF in the
hippocampus.
From Salas –Ramirez et al 2015
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Overall, this study supports the usefulness of the rodent animal model in examining the effects of
AC Chemotherapy on cognitive processes. We and others have demonstrated impairment in
hippocampal dependent memory (Salas-Ramirez et al., 2015; Kitamura et al., 2015). The
differential expression and activation of signaling proteins in ovary-intact and OVX female rats
demonstrate the complexity of the other biological factors such as menopausal status on the
molecular signature of chemotherapy-related cognitive impairment.

32

Chapter 2.2 Methods: Chemotherapy -mediated Cognitive Impairment in the Menopausal
Model Rat
Antibodies
The chemotherapy drugs used in the study, cyclophosphamide and doxorubicin were obtained
from LKT Laboratories. Antibodies against phospho c-Jun Ser73 (D47G9) and total c-Jun
(60A8); phospho- ERK and total ERK; Phospho JNK/SAPK; total Trk B(80E3) and cFOS (9F6)
were obtained from Cell Signaling Technology. Mouse monoclonal antibody against phospho
Trk (E6), Arc/Arg3.1 (C-7), phospho- Creb-1 (Ser133) and total Creb-1 (24H4B), and Homer-1a
(M-13) were obtained from Santa Cruz Biotechnology. Mouse monoclonal antibody against beta
actin (BA3R), GAPDH and the 8-OHdG/8OHG antibody (15A3) was purchased from Thermo
Scientific. Total JNK/SAPK and BDNF was purchased from Novus Biologicals.
All experiments were conducted according to protocols approved by the lnstitutional
Animal Care and Use Committee at The City College of New York. Ovariectomized female
Sprague Dawley rats at the age of 8-10 weeks were obtained from Charles River (location). Rats
were divided into two groups, vehicle (n=6-8) and chemotherapy (n=6-8) for subsequent
molecular or immunohistochemical studies. The data presented in this dissertation come from a
larger study that also addressed the influence of hormonal status in CRCI (Salas –Ramirez et al.,
2015) Drug treatments were carried out as described previously (Salas- Ramirez et al., 2015).
Briefly, rats in the chemotherapy groups were intravenously injected once a week for three
weeks with the combination of cyclophosphamide (40mg/kg; LKT Laboratories) and
doxorubicin (4 mg/kg; LKT laboratories) prepared in 0.9% saline solution. The vehicle
control animals were administered an equal volume of saline.
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Molecular Studies: Protein Extraction and Western Blot Analysis
One week following the last injection, rats were euthanized by decapitation for the collection of
tissue for the biochemical analyses. Whole brains were rapidly removed and the tissues of
interest (hippocampus and prefrontal cortex (PFc)) was isolated on ice from each hemisphere,
flash frozen in liquid nitrogen and stored at -80 C until further processing. For protein
o

extraction, brain tissue from one hemisphere of each animal was homogenized as described
previously (Salas- Ramirez et al., 2015). Briefly, tissue was lysed in ice-cold NP40 buffer
(40mM Tris–HCl pH 7.5, 274 mM NaCl, 2 mM EGTA, 20% v/v glycerol, 50 mM NaF, 1 mM
Na3VO4, 1mM beta-glycerophosphate, 1 mM PMSF, 2.5 mM sodium pyrophosphate, 1% NP40, and protease inhibitor cocktail (Thermo scientific) using a BioMasher single use
homogenizer and clarified by centrifugation at 14,000 x g for 15 min at 4°C. Protein
concentrations were determined using the micro BCA protein essay (Pierce) using bovine serum
albumin as a standard according to manufacturer’s protocol.
Thirty micrograms of protein from the hippocampal and PFC brain tissue were loaded in each
lane and electrophoretically separated on either 10% or 12% SDS- PAGE gels and transferred
onto a PVDF membrane. The membranes were blocked in 5% nonfat dry milk for one hour at
room temperature and subsequently incubated with specific primary antibodies overnight at 4°C.
Following several washes, membranes were incubated for one hour with the appropriate HRPconjugated secondary antibodies. The immune complexes were detected by the enhanced
chemilluminescence (ECL) detection system (GE) and signal intensities were quantified by
Image J using b actin as a loading control.
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RNA Isolation and Quantitative Real-Time PCR
Total RNA was extracted from the hippocampus or PFc of the remaining hemisphere from each
animal in TRI Reagent (Invitrogen) according to the manufacturer’s instructions and incubated
with DNase I to remove contaminating genomic DNA. RNA quality was assessed by agarose gel
electrophoresis and the concentration was quantified using the NanoDrop spectrophotometer. All
RNA samples used in the study obtained A260/A280 ratios greater than 1.8-2.0.
Total RNA samples (500ng) was heat denatured at 65 C for 5 minutes and immediately cooled
o

on ice. Complementary DNA (cDNA) was synthesized using a random hexamer/ anchored oligo
dT primer mix according to the Verso cDNA synthesis protocol (Thermo Fisher Scientific). PCR
amplification of cDNA was carried out with Power Up SYBR Green Master Mix (Thermo
Fisher) using gene specific primers (Table 1). PCR products were monitored using the Applied
Biosystems 7500 Real-Time PCR System and amplicon specificity was confirmed by melt curve
analysis. Fold changes in gene expression relative to saline controls was calculated using the
Comparative CT method, with reference to the housekeeping genes b actin and gapdh. Statistical
analysis for each target gene was performed on ΔCT values between saline and chemotherapy
treated groups.
Immuno-Northern Blot Analysis of 8-OH(d)G
Three micrograms of total isolated RNA from the hippocampus were prepared in sample buffer
(20 mM MOPS, 5 mM sodium acetate, 1 mM EDTA, 2.2M formaldehyde, 50%(v/v) formamide,
and heat denatured at 65 C for 15 minutes. RNA samples were immediately placed on ice and
o

mixed with tracking dye containing SYBR Safe (Thermo Fisher) before being loaded onto (.8%1%) agarose gels prepared in 1X Formaldehyde buffer (20mM MOPS, 5mM sodium acetate,
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1mM EDTA, 2.2M formaldehyde) (Mishima et al., 2015). After electrophoresis, gels were
visualized using a blue light illuminator to visualize the prominent ribosomal bands and to
confirm equal loading. Capillary transfer of RNA onto positively charged Nylon membranes
(Biodyne B, Thermo Sci) were carried out in 20X SSC buffer overnight. Membranes were
exposed to UV irradiation (Hoefer UVC500) to crosslink RNA to the filter. Transfer efficiency
was confirmed by methylene blue staining. The membranes blocked for 1 hour in 5% bovine
serum albumin in Tris buffered Saline and 0.1% Tween 20 and then incubated in the primary
monoclonal antibody 8-OHdG/ 8-OHG (1:5000, Thermo Fisher) overnight at 4 C. After washing
o

in Tris-buffered saline with Tween 20, membranes were incubated in horseradish peroxidaseconjugated mouse secondary antibody (1:3000) for 1h. Chemiluminescent signals were detected
using the SuperSignal West Pico Substrate (Thermo Scientific) and exposed to Clxsposure film
(Thermo Scientific). Alternatively, membranes were incubated in secondary Donkey anti-Mouse
IRDye 680 (1: 10,000, LI-COR Biosciences) and scanned on the Odyssey® Classic Infrared
Imaging System (LI-COR).
Dot Blot Analysis of RNA Oxidation
One microgram of unfractionated total RNA was heat denatured in a solution of 50%formamide/
2.2 M formaldehyde according to the procedures of Brown, Mackey, Du (2004). Denatured RNA
samples were immobilized onto positively charged nylon membranes using the Bio –Rad
microfiltration apparatus and crosslinked by UV irradiation. The membrane was blocked for one
hour in 5% bovine serum albumin in Tris Buffered Saline and Tween 20 (TBS-T) and
subsequently probed with the anti 8-OHdG antibody overnight at 4C. After washing in TBS-T,
membranes were incubated with HRP-conjugated anti mouse secondary antibody and signals
were detected by ECL as described previously. Specificity of oxidized RNA was confirmed by
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preincubation of RNA with RNase prior to membrane blotting.
Immunohistochemical Analysis of OH(d)G adducts and MAPK Phosphorylation
Brain tissue from a separate cohort of animals (N=5) were used to determine the levels of nucleic
acid oxidation by semi-quantitative immunohistochemistry. The animals used in these studies
were anesthetized with an overdose of pentobarbital and perfused transcardially with heparinized
saline followed by 4% paraformaldehyde. Afterwards brains were post-fixed for 1 hour and
placed in 20% sucrose/phosphate buffered saline solution. Brains were sectioned at 40 microns
and were stored in a cryopreservative under -20 C until use.
o

Immunohistochemical procedures were conducted on paired free-floating coronal sections from
the brains of saline and AC chemotherapy- injected rats. Heat-induced antigen retrieval was
performed on slices using an antigen unmasking solution (Vector) and subsequently placed in
0.3% hydrogen peroxide solution to quench endogenous peroxidase activity. Sections were
blocked with 3% Normal Goat serum with 0.4% Triton X-100 for 1 hour and then incubated with
a mouse monoclonal anti 8-OHdG antibody (Thermo Fisher) overnight at 4 C. The omission of
o

primary antibodies from the blocking solution served as a negative control. Biotinylated mouse
secondary antibodies were added to sections for 1 hour and detection of antigen was carried out
using a Vectastain ABC kit (Vector Laboratories) using 0.03% hydrogen peroxide and DAB
substrate as a chromogen. Sections were mounted onto Superfrost coated slides, air dried
overnight and dehydrated in increasing alcohol concentrations before being defatted in xylene
and cover slipped in Permount mounting medium.
Photomicrographs were acquired from the regions of interest using a Zeiss Axioplan 2
microscope with Nikon NIS-Elements under standardized conditions including white balance.
37

Images were exported as TIFF files and semi-quantitative analysis on the converted 8-bit images
was carried out with the ImageJ software(NIH). A threshold level was set and applied to all
images for comparison. The percent area occupied by signal in 5 fields of each region of interest
was measured and the averages were compared between chemotherapy and saline-control
groups.
To exclude the possibility that peroxidase quenching induced 8-OHdG adducts, the incubation of
hydrogen peroxide was omitted prior to immunofluorescence procedures conducted in parallel
tissue slices. Sections were similarly blocked in 3% normal goat serum with 0.4% Triton X-100
for 1 hour and subsequently double-labelled with the anti 8-OHdG antibody and the neuronal
marker anti-NeuN at 4 C overnight. After extensive washing in PBS, sections were incubated in
o

Alexa-647 conjugated anti-mouse and Alexa-488 conjugated anti rabbit secondary antibodies for
2 hours in the dark at room temperature. The sections were washed and cover slipped in
fluorescence mounting medium (Dako) containing the nuclear marker 4’, 6-diamidino-2phenylindole (DAPI). Immunofluoresence images were obtained using a Zeiss LSM710 laser
scanning confocal microscope.
To examine the status of ERK activation in the brains of chemo-treated animals,
immunohistochemistry was performed for phosphorylated ERK 1/2 (Thr202/Tyr204) following
the procedure described previously. A qualitative assessment of positive ERK detection was
carried out by analyzing strong nuclear staining.
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Rat Cytokine Arrays and Image Analysis
Rat cytokine profiling was performed using a membrane –base sandwich immunoassay
Proteome Profiler Rat Cytokine Array Kit (Panel A, R&D Systems). Hippocampal tissues were
removed from saline and AC chemotherapy treated rats and prepared as described previously in
the Materials and Methods section. 400 micrograms of tissue lysate were mixed with a cocktail
of biotinylated detection antibodies and incubated at room temperature for one hour. The
lysate/antibody mixture was then added to membranes spotted with capture antibodies and
incubated overnight at 4 C. Membrane arrays were extensively washed to remove unbound
o

antibodies and Streptavidin-HRP and a chemiluminescent reagent mix was then applied. The
membrane arrays were exposed to autoradiography film at several time points. Pixel densities
from each membrane (N=6) was analyzed using the semi-automated Quick Spots image analysis
software from Western Vision Software.
BDNF ELISA: Frontal Cortical tissue
A commercially available ELISA kit (ERBDNF, Thermo Fisher) was used to quantify the levels
of Brain Derived Neurotropic factor in frontal cortex of rats. Initially, frontal cortices were
isolated from the brains of saline or AC Chemotherapy injected rats, rinsed in ice cold PBS to
remove blood, and snap frozen in liquid nitrogen. Samples were stored at -80 C until use. Frontal
o

cortices were homogenized in ice cold NP-40 buffer as described in earlier studies and the total
protein content was quantified according to the BCA protein assay protocol. The procedure for
the ELISA assay was carried out according to manufacturer’s recommendations. In brief, 100
micrograms of total protein from each sample was prepared in the provided diluent buffer and
100ul was added to the wells of a precoated anti-rat BDNF antibody plate in duplicate. 100 ul of
BDNF standards (12.29 pg/ml – 3000 pg/ml recombinant rat BDNF) were also applied to the
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plate in duplicate. The plate was covered and incubated overnight with gentle rocking at 4 C. The
o

plate was then washed and incubated for one hour with a biotinylated antibody reagent.
Subsequently, the plate was washed, incubated for 1 hour with a streptavidin-HRP solution and
developed in the dark for 30 minutes in TMB (3,3',5,5'-Tetramethylbenzidine) chromogenic
substrate. The absorbance of the samples and standards were measured on a plate reader at a
filter set at 450nm and 550nm. A standard curve was generated to extrapolate the concentration
of BDNF in the samples.
Statistical Analysis
All data was analyzed comparing the two groups, saline and chemotherapy treatment in the
hippocampus or prefrontal cortex. Values are expressed as the mean + SEM. Comparison were
carried out after verifying normal distribution with a t test or with non-parametric MannWhitney test when appropriate. Statistical analyses were performed with Graph Pad Prism
version 5 (GraphPad Software, Inc., San Diego, CA). Differences between groups were
considered to be significant at a p value of <0.05.
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Table 1: Oligonucleotide primers used in this study.

Target Gene

Accession
Number

Sequence (5'->3') F/R

ARC

NM_019361.1

GAGAGCTGAAAGGGTTGCAC
GCCTTGATGGACTTCTTCCA

BDNF

EF125690.1

AAGGCTGCAGGGGCATAGAC
TGAACCGCCAGCCAATTCTC

CFOS

NM_022197.2

TTCACCCTGCCTCTTCTCAATGAC
GCCTTCAGCTCCATGTTGCTAATG

CJUN

NM_021835.3

CAATGGGCACATCACCACTACAC
TCTGGCTATGCAGTTCAGCTAGG

CREB

NM_134443.1

CGTCATCTGCTCCCACTGTA
CCTTCGTTTTTGGGAATCAG

HOMER1A

AJ276327.1

CAAACACTGTTTATGGACTG
TGCTGAATTGAATGTGTACC

HO-1

NM_012580.2

GAGCGAAACAAGCAGAACCC
ACCTCGTGGAGACGCTTTAC

CATALASE

NM_012520.2

GAGAGGAAACGCCTGTGTGA
TTGGCAGCTATGTGAGAGCC

COX2

NM_017232.3

TGTATGCTACCATCTGGCTTCGG
GTTTGGAACAGTCGCTCGTCATC

GPX1

NM_030826.4

GCTCACCCGCTCTTTACCTT
GATGTCGATGGTGCGAAAGC

NFKB p65

NM_199267.2

TGGACGATCTGTTTCCCCTC
CCCTCGCACTTGTAACGGAA

PRDXN1

BC058450.1

GGCACGTCTTCCTGTGTTCT
TTGAAGCTGGGAGCAGGATG

Cu/Zn SOD1

NM_017050.1

CAGCGGATGAAGAGAGGCAT
ACGGCCAATGATGGAATGCT
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Table 1 continued: Oligonucleotide primers used in this study.
MnSOD

NM_017051.2

CGGGGGCCATATCAATCACA
GCCTCCAGCAACTCTCCTTT

THIOREDOXIN

BC058454.1

AGGTTGGGGAGTTCTCTGGT
TGGAGCTGGTCACACTTTTCA

TNFa

NM_012675.3

CCAGGAGAAAGTCAGCCTCCT
TCATACCAGGGCTTGAGCTCA

TNFR1

NM_013091.1

AAGTGCCACAAAGGAACCTACT
ACACACCTCGCAGACTGTTT

TRKB.-T1

NM_001163168.2

CGGGAGCATCTCTCGGTCT
AGGGGGATCTTATGAAACAAA

TRKB.FL

NM_012731.2

ATGCTGCACATCGCTCAGCA
ATGGGCAACATTGTGTGGCC

b ACTIN

NM_031144.3

GCAGGAGTACGATGAGTCCG
ACGCAGCTCAGTAACAGTCC

GAPDH

XM_017593963.1

TGATTCTACCCACGGCAAGTT
TGATGGGTTTCCCATTGATGA
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Chapter 2.3 Results
2.3.1 BDNF levels are unaffected in the PFc
It has been suggested that the levels brain-derived neurotrophic factor (BDNF) may be
implicated as a contributory player in chemotherapy –related cognitive impairment. In an earlier
study, our lab has observed that the levels of BDNF in the hippocampus were unaffected after
AC chemotherapy treatment in the ovary-intact and OVX rat models of CRCI. In the present
study, the levels of the neurotrophin was examined in the prefrontal cortices of the OVX postmenopausal rat model using a commercial BDNF ELISA (Enzyme linked Immunosorbant
Assay) kit. As shown in Figure 2.4, there were no differences found between the levels of the
BDNF in the prefrontal cortex (PFc) of saline and AC chemotherapy groups. Additionally, the
expression of the mature isoform of BDNF were unaffected as supported by western blot
analysis (Figure 2.4).
2.3.2 The activation and expression of the TrkB isoforms
The actions of BDNF are mediated through the activation of the Trk (Tropomoysin
Receptor Kinase) family of receptors (Minichiello, 2009). Therefore, using immunoblot analysis,
the activation and expression of the TrkB isoforms (full length and truncated) were also
measured in the hippocampus and the prefrontal cortex of the animals. A significant increase in
phosphorylated (Y516) TrkB was observed in the hippocampus of AC –chemotherapy groups
(p<0.05, Figure 2.6 B). In contrast, a decline in TrkB receptor activation was found in the
prefrontal cortex (PFc) of AC –chemo animals (p<0.05, Figure 2.5 B). Furthermore, in the
hippocampus, a significant increase in the protein levels of the full length Trk B isoform (Figure
2.6 C) was observed in animals after chemotherapy exposure. No significant differences were
found in the RNA or protein levels of the truncated TrkB isoform (Figure 2.6 C, D). In the PFc ,
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no differences were observed in the TrkB isoform protein levels , although there was a trend
towards an higher Trk full –length expression in AC-chemotherapy groups (Figure 2.5 C).
Additionally, the mRNA levels of the full-length receptor were found to be significantly higher
in treated animals (p<0.05, Figure 2.5 D).
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Figure 2.4: Brain-derived neurotropic factor (BDNF) protein levels (pg/mg of
homogenized sample) in the frontal cortex were measured with ELISA. There were no
differences between the levels of the neurotrophin in the frontal cortex of saline and AC
chemotherapy groups. N=6, error bars indicate S.E.M.
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Figure 2.5: Levels of TrkB receptor activation and TrkB receptor isoforms in the PFc. (A)
Representative immunoblot analysis of phosphorylated Trk B receptor (Ty516) and total Trk B
expression. (B) Chemotherapy treated rats display significantly lower levels of activated TrkB
receptor and (D) higher full length TrkB isoform mRNA expression. (E) No significant differences
in BDNF levels . N=6/group; *p<0.05
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Table 2: Description of the immediate early gene products evaluated in the study.
Immediate Early
Gene
Arc/Arg3.1
Activity-regulated
cytoskeletal-associated
protein

Function(s)
In association with F-actin, Arc localizes to postsynaptic density (PSD) 95 and
NMDA receptor complexes in the PSD. (Husi et al., 2000)
Acts as a key regulator of synaptic plasticity. Arc is required for protein synthesisdependent forms of long-term potentiation (LTP) and depression (LTD) and for the
formation of long-term memory. (Bramham et al., 2010)
Arc promotes the endocytosis of AMPA receptors (AMPARs) in response to
synaptic activity, thereby maintaining the levels of surface AMPARs in response to
chronic changes in neuronal activity through synaptic scaling, a form of homeostatic
plasticity. (Korb et al., 2013)

BDNF
Brain derived
Neurotrophic Factor

Neurotrophin that promotes the survival and differentiation of selected neuronal
populations during development.
Implicated in axonal growth, axonal pathfinding, the modulation of dendritic growth
and morphology.
Role in synaptogenesis and synaptic plasticity, through modulatory effects on
neurotransmitter release and long-term potentiation (LTP) at adult synapses.

c FOS

Proto-oncogene encoding for a transcription factor that is induced in response to
neural activity and other stimuli
The translated protein product Fos can dimerize with members of Jun family in
order form the Activator Protein-1 heterocomplex (AP-1). This transcription factor
mediates the expression of genes involved in cell proliferation and differentiation,
and activity dependent synaptic changes.

c Jun

CREB
cyclic AMP (cAMP)
response elementbinding protein

Homer1a

Transcription factor that dimerizes with Fos family members to form the AP-1.
Plays an important role in neuronal apoptosis and neurons survival (Jochum et al.,
2001)
The JNK (c-jun kinase)/c-Jun cascade is activated by various stimuli including
stress, ischemia, and stroke, seizures, learning and memory, axonal injury (Raivich
and Behrens, 2006).
Transcription factor that regulates transcription of prosurvival target genes such as
such as c-fos, Bcl-2, and BDNF.
Several intracellular signaling cascades culminate in the phosphorylation of CREB.
Upon activation, CREB forms a functionally active dimer that binds the cis-acting
cAMP response elements (CRE) within the promoters of target genes.
A short inducible isoform of the Homer gene family (Ménard and Quirion, 2012).
Encodes a scaffolding protein, mainly localized at the glutamatergic postsynaptic
density (PSD) of dendritic spines.
Homer1a protein disassembles constitutive Homer1b/c isoform clusters that bridge
intracellular receptors to other PSD scaffolding proteins.
Homer1a acts as a dominant negative modifier of synaptic architecture.
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2.3.3 Analysis of immediate early gene (IEG) products in the hippocampus and PFc
The phosphorylation status and expression pattern of downstream immediate early gene (IEG)
products (described in Table 2) related to BDNF-TrkB signaling were evaluated in the
hippocampus and PFc using western blot analysis and RT-qPCR. In the hippocampus of AC
chemotherapy –treated rats, the protein levels of arg3.1/arc, and total Creb-1 protein were
significantly higher relative to saline controls (p<0.05 Figure 2.8, 2.9) The phosphorylated levels
of c Jun were also found to increase after treatment (p<0.01). The relative levels of BDNF,
CREB, and HOMER1A mRNA were also significantly higher in AC chemotherapy treated
groups (p< 0.05, Figure 2.7).

Fold Change in mRNA (Relative to saline)
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Figure 2.7 :qPCR analysis of immediate early gene (IEG) products in the
hippocampus. Gene expression was normalized to the average expression of GAPDH and
represented as the fold change in chemo-treated rats relative to saline controls using the 2ΔΔCT method. Data represents mean +SEM. Results indicate the differential mRNA
expression of select IEGS. The relative levels of BDNF, CREB, and HOMER1A were
significantly higher in chemotherapy treated groups .(*p< 0.05)
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Figure 2.8: Western Blot analysis of
immediate early gene expression in
the hippocampus. Higher levels of
Arc/arg3.1 was observed in the
hippocampus after treatment.
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Figure 2.9: Western Blot analysis of immediate early gene expression in the hippocampus.
There were no differences in Creb activation, but a significant increase in total- Creb protein after
chemotherapy (*p <0.05) . The levels of phosphorylated cJun were also higher in treated rats
(*p<0.01) .
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In the PFc , there were significantly lower levels of total Creb-1 protein in AC-treated animals
(p<0.05, Figure 2.11). There were no differences detected at both the mRNA and protein levels
of the panel of IEGs in either group (Figure 2.10).
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Figure 2.10: qPCR analysis of immediate early gene (IEG) products in the PFc. Gene expression
was normalized to the average expression of GAPDH and represented as the fold change in chemotreated rats relative to saline controls using the 2-ΔΔCT method. Data represents mean +SEM.
Results indicate the differential mRNA expression of select IEGs. There were no differences in IEG
mRNA expression between AC-chemo and saline groups.
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Table 3: Summary of mRNA and protein expression changes in the hippocampus and prefrontal cortex (PFc)
after AC Chemotherapy. Significant level was set at P<0.05. ↑ Increased, ↓ Decreased. N.S. denotes not significant.

2.3.4 Analysis of oxidative stress -responsive gene expression in the hippocampus and PFc
Using RT-qPCR analysis, the mRNA expression of antioxidant and oxidative-stress responsive
genes were measured. In the hippocampus the relative levels of GPX1 (glutathione peroxidase
1), NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells, p65 subunit),
PRDX1(peroxiredoxin-1) and TNFa (Tumor necrosis factor alpha) were all significantly higher
in AC chemotherapy groups relative to saline controls. The levels of HO-1(Heme oxygenase 1)
were decreased in chemo- treated animals (p< 0.05, Figure 2.12). The relative levels of
CATALASE, GPX1, NFkB, PRDX1, THIOREDOXIN, and TNFa were significantly higher in the
PFc of AC –chemotherapy animals (p<0.05, Figure 2.13).
2.5
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Fold Change in mRNA Expression
(Relative to Control)

2

*

*

1.5

1

*

0.5

0

Figure 2.12: Analysis of oxidative stress -responsive gene expression in the hippocampus by
qPCR in rats after chemotherapy treatment. Gene expression was normalized to the average
expression of GAPDH and represented as the fold change in chemo- treated rats relative to saline
controls using the 2 method. Error bars indicate +SEM. The relative levels of GPX1, HO-1, NFKB,
PRDX1 and TNFa were significantly higher in chemotherapy groups (*P< 0.05).
-ΔΔCT
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Figure 2.13: Analysis of oxidative stress -responsive gene expression in the PFc by
qPCR in rats after chemotherapy treatment. The relative mRNA expression of genes
related to oxidative stress were evaluated in the hippocampus and prefrontal cortex of
chemotherapy treated rats compared to saline controls. Fold changes were quantified
using the 2 method and normalized to the levels of GAPDH. Error bars represent the
SEM. * p< 0.05 vs saline group
−ΔΔCt
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2.3.5 ERK/MAPK and JNK/SAPK phosphorylation is higher in the brains of animals after AC
chemotherapy treatment
MAPK cascades are known to be involved in a number of stress response signaling pathways. In
an earlier study, the phosphorylated levels of ERK/MAPK were found to be significantly higher
in hippocampal lysates from OVX –AC chemotherapy treated groups relative to OVX-saline
control rats. In this study, the activation of the ERK/MAPK and the JNK/SAPK pathways were
measured. Significantly higher levels of phospho-ERK1/2 Thr202/Tyr204 (p<0.05, Figure 2.14
B) and phospho-JNK/SAPK Thr183/Tyr185 (p=0.036, Figure 2.15) were detected in the
hippocampus of AC-treated rats. Furthermore, the increase in phosphor ERK levels were
supported by the qualitative assessment of immunohistochemical staining in the dentate gyrus
and CA3 regions of the hippocampus of similarly treated AC-chemotherapy rats (Figure 2.14
A). In the PFc, there were according to immunoblot analysis, although there was a trend
increased p-JNK/SAPK expression in AC-chemo groups (Figure 2.16).
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Figure 2.14: Phosphorylated ERK in the hippocampus of rats after systemic chemotherapy
treatment. A. Representative images of Immunohistochemical staining of the active form ERK in the
dentate gyrus (i,ii) and CA3 region (iii,iv) of the hippocampus of saline or chemotherapy treated
animals. N=3 rats B. Western analysis of phospho-ERK detection in hippocampal lysates. Quantitative
representation (mean + standard error) of immunoblots demonstrate that chemotherapy treated animals
exhibit higher levels of activated ERK in the hippocampus. N=10 rats, p<0.05. Scale bars=100 µm
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Figure 2.15 : JNK/SAPK phosphorylation is higher in the hippocampus of chemotherapy
treated animals. A,B. Representative immunoblots demonstrate that the activated levels of
SAPK/JNK is higher in the hippocampus of chemo-treated rats ( N=7) relative to saline controls
(N=6 rats). Data represents the mean + SEM fold change from saline group. p<0.05
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Figure 2.16: Levels of ERK/MAPK and JNK/SAPK activation in the PFc after AC Chemotherapy. (A)
Representative immunoblots demonstrate that are no significant differences observed in the phosphorylated levels of
ERK1/2 (B) or JNK/SAPK (C) in the PFc of saline of chemotherapy –treated groups. P<0.05. Not significant n.s.,
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2.3.6 Cytokine and Chemokine levels are altered in the hippocampus of chemotherapy treated
animals
Clinical and experimental evidence indicate that pro-inflammatory cytokines may be
mediators of chemotherapy-associated cognitive impairment. In the present study, the relative
levels of various cytokines and chemokines were determined simultaneously using a membranebased antibody array (R&D, ARY008). The 29 cytokines included in the array is shown in
Figure 2.17 B.
Increases of >1.5 fold was measured for IFN-gamma, IL-2, IL-3, IL-4, IL-6, IL-10, LIX,
L-Selectin, MIG, MIP-1alpha, MIP-3alpha, VEGF, GM-CSF, ICAM-1, IL-1ra, IL-17, IP-10,
TNF-alpha in the hippocampal lysates of AC-chemotherapy treated animals (Figure 2.17 C).
There was also a reported decrease in the relative levels of Thymus Chemokine (CCXL7) in
treated animals compared to saline controls.

Figure 2.17: Cytokine production was evaluated using Proteome Profiler multianalyate
arrays as described in materials and methods. A. Representative cytokine panel of protein
lysates prepared from the hippocampus of saline or AC chemotherapy-treated rats. Data shown
are from a 10 minute exposure to x-ray film. C. Densitometric analyses of the antibody arrays.
The mean signal intensity of the cytokine/chemokine spots was divided by the mean signal
intensity of the reference spots for each membrane. The column graphs display the fold changes
in the mean spot density of AC chemotherapy groups compared to saline controls. N=6
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2.3.7 Oxidative damage in the hippocampus is associated with AC chemotherapy
To address if systemic chemotherapy is associated with oxidative modifications to
nucleic acids in the brain, the levels of the DNA/RNA Oxidation marker 8-OH(d)G was
evaluated in RNA isolated from the hippocampus of AC-chemotherapy treated rats. Immuno-dot
blot analysis was performed on unfractionated total RNA (See methods). Increased 8-OH(d)G
immunoreactivity from AC chemo- treated groups was observed relative to the saline controls
(Figure 2.18). Immuno-Northern blot analysis of 8-OH(d)G was also performed on total RNA
that was electrophoretically separated on a denaturing formaldehyde gel (Figure 2.19 A). The
densitometric analysis of oxidation marker indicates that AC chemotherapy treated animals
exhibit significantly higher levels of oxidized 28S ribosomal RNA bands than saline- controls in
the hippocampus (Figure 2.19 B).

Immuno-dot blot of
8-hydroxy-guanosine

Methylene Blue

Figure 2.18: Immuno-dot blot analysis of unfractionated total RNA from hippocampus of
saline or chemotherapy treated animals for the detection of 8-Hydroxyguanosine (8-OHG).
The same blot is shown in the lower panel and total RNA was visualized with methylene blue
staining. The increase of 8-OH(d)G immunoreactivity in AC Chemotherapy –treated animals was
assessed by densitometry.
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Figure 2.19: Total RNA (2 μg) isolated from the hippocampus was analyzed by methylene blue staining and INB
(immuno-northern blot) with anti-OH(d)G antibody after electrophoresis in 1% agarose denaturing gel (see materials
and methods). Long and short exposures of the INB are displayed (A). Chemotherapy treated animals (N=6) have
significantly higher levels of oxidized 28S ribosomal RNA bands than saline- controls (B). Densitometric analysis was
performed to quantitate the band intensities. Data were expressed relative to the band intensity of saline groups (N=5).
Values are shown as the mean ± SEM. *P < 0.05

A.

Fold OH(d)G immunoreactivity over saline

The levels of 8-OH(d)G were further validated using immunohistochemical methods (Figure
2.20 A). Tissue section staining and image acquisition were performed in parallel for the
entire set (N=5/group) using the ImageJ software immunohistochemistry plugin (NIH). Positive
8-OH(d)G staining was assessed by initially setting a “threshold” using the thresholding tool, and
was applied to all images to be compared. Within each region of interest (ROI) in the
hippocampus, the percent area occupied by 8-OH(d)G stain (brown) in 5 fields was measured. In
AC chemotherapy- treated animals, increased neuronal staining for 8-OHdG was observed in
various hippocampal brain regions (Figure 2.20 B). Semi-quantitative analysis of the staining
patterns suggests a higher percentage of 8-OH(d)G area intensities in the CA1 and CA3 regions
of the hippocampus relative to control animals (p<0.05, Figure 2.20). Fluorescence microscopy
procedures further demonstrate that the cells expressing 8-OHdG are also co-labeled with NEUN
(Figure 2.21). These modifications indicate that induction of oxidative stress by chemotherapy
may be selective to specific cell populations, particularly neurons that exhibit a greater intrinsic
vulnerability to stress (Wang and Michaelis, 2010).
The data presented in this chapter demonstrate that the changes in IEG expression after
AC chemotherapy were more robust in the hippocampus than in the PFc region of the animals
(Table 3). Considering the impaired performance on behavioral tasks that require the
involvement of both brain regions, it was expected that there would be similar effects on gene
expression profiles or phospho-Trk B immunoreactivity. The hippocampal and PFc regions
exhibit genomic and epigenetic adaptations in response to adverse stimuli that can contribute to
cognitive deficits and behavior alterations (McEwen et al., 2016). The cell populations and
circuits involved these adaptions are likely to mediate behaviors that are carried out through
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different mechanisms in discrete brain areas. The finding that chemotherapy leads to elevated
inflammatory and oxidative stress-responsive gene expression in the PFc and hippocampus
represents a common feature and potential mechanism that is shared between these regions. The
BDNF –Trk B pathway facilitates positive effects on different cellular processes, but the
modulation of signaling after chemotherapy is likely to be mediated independently of the overall
inflammatory response induced in the brain after treatment. The levels of the biomarker 8-OHdG
and oxidative damage were not evaluated in the PFc. It is likely that these oxidative
modifications may also be observed in other regions of the brain and will be addressed in future
studies.
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Figure 2.20 : Representative
photomicrograph of 8-oxo-7,8dihydroguanosine (8-OHG)/ 8-oxo7,8-dihydro-2-deoxyguanosine (8OHdG) immunohistochemistry in
the dentate gyrus, CA3 and CA1
regions of saline and chemo-treated
rats (A). Magnification:40x; 200x. In
chemo-treated animals, increased
neuronal staining for 8-OHdG was
observed in the hippocampal brain
regions. Semi quantitative image
analysis of 8-OHdG staining intensity
as described in Materials and
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from N=5 animals per group and
presented as the mean ± SEM. Scale
bar: 100 µm.

3
% 8OHdG/8OHG Area (Relative
to control)

B.

2.5
2

1.5

p <0.03

Saline
Chemo

p <0.05

n.s.

1

0.5
0

DG

CA3

CA1

65

66

Figure 2.21: Detection of 8-hydroxyguanine 8OH(d)G in the dorsal hippocampus CA1 region of AC-chemotherapy
treated rats. Double immunofluorescence of hippocampal tissue sections with antibodies specific to NEUN demonstrate
8-OH(d)G labeling is restricted to neuronal cell types

Chapter 2.4 Discussion
The biological effects of BDNF have been extensively studied in the mammalian brain.
Early evidence have implicated the expression levels, functionality, and genetic polymorphisms
of the neurotrophin in the occurrence of chemotherapy-associated cognitive impairment (Dooley
et al., 2016; Ng et al., 2017). In the present study, we employed ELISA and immunoblot analyses
to examine the expression and activity of the BDNF-TrkB pathway in the hippocampus and
prefrontal cortex of saline-control and AC Chemotherapy-treated rats. In accordance with a
previous study (Salas-Ramirez et al., 2015), no differences were indicated in the levels of BDNF
in either brain region of the control and treated animals (Figure 2.3 ,2.4). BDNF is initially
synthesized and localized intracellularly as a 32 kDa precursor protein (proBDNF), which is then
cleaved by several proteases to produce either a 14kDa mature form (mBDNF) or a truncated
form of 28 KDa (Mowla et al., 2001). Although the secreted mature BDNF form is generally
assumed to be biologically active, the proBDNF form can produce opposing biological effects
mediated through the p75 neurotrophin receptor (Woo et al., 2005). The antibodies supplied in
commercial ELISA kits used in this study (ERBDNF, Thermo Fisher) detect both the precursor
and mature isoforms of BDNF. Therefore, western analysis using antibodies specific to the
mBDNF was necessary to interpret the ELISA findings. Consistent with the results reported from
the ELISA assay, no differences were found in the protein expression of mBDNF of either brain
region (Figure 2.5). BDNF isoform mRNA expression was assessed by quantitative PCR, using
primers specific to BDNF exon IX, the 3’ coding exon that is which is included in all splicing
variants and encodes the BDNF preprotein amino acid sequence (Aid et al., 2007). In contrast to
protein levels, a significant 1.8-fold increase in BDNF expression was observed in the
hippocampus of AC-Chemo treated animals (Figure 2.7). It is important to note that mRNA and
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protein levels are not always correlated in vivo as a result of several dynamic regulatory posttranscriptional/ translational and degradation mechanisms (Liu et al., 2016).
Although no significant changes were observed in BDNF protein expression, the activity
of the TrkB receptor was measured after treatment. Using a monoclonal antibody that detects
phosphorylation motifs of the receptor at adapter protein docking sites, we observed a significant
increase and decrease in TrkB receptor activation in the hippocampus and prefrontal cortex of
AC chemo- treated groups, respectively (Figure 2.5, 2.6). Furthermore, treatment was associated
with increased expression of the full length Trk B (trkB-FL) receptor in these brain regions. This
full-length isoform comprises an intracellular catalytic tyrosine kinase domain that is responsible
for transmitting the effects of BDNF binding to downstream signaling molecules (Minicheiello et
al., 2009). These reported changes in BDNF ligand or Trk B receptor isoform levels could
contribute to alterations in plasticity of the brain regions observed in chemotherapy-treated rats.
Psychosocial and physiological stressors are associated with cancer and cancer- related
therapies. Furthermore, the concomitant structural and functional changes likely involve
alterations in gene expression that influence cognitive processes in the brain. We sought to
examine whether the expression of several immediate early gene (IEGs) products would be
altered in the brain in response to chemotherapy. The panel of IEGs evaluated in this study have
important regulatory roles involving the cellular stress response, survival, learning and memory
(Table 2) . In the hippocampus, western blot analysis revealed a significant increase in the
expression of arc, creb and phospho- c Jun, with general trend of higher cFOS and homer1a
protein expression in AC chemotherapy–treated rats (Figure 2.8. 2.9) . Moreover, q PCR
analysis also indicated significant BDNF, CREB and HOMER1A mRNA levels in this group
(Figure 2.7). We observed a significant decrease in creb protein in the prefrontal cortex of AC
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chemotherapy-treated rats, with a general decreasing trend of arc and phospho-creb and
increased homer1a protein expression (Figure 2.11). Interestingly, these alterations in gene
expression appear to relate to the upstream events and activation status of the TrkB receptor. The
BDNF/TrkB signaling pathways are involved in the transcription, translation, and mobilization
of various proteins and has been implicated in several forms of synaptic and structural plasticity
(Yoshii and Martha Constantine-Paton, 2011). It is unclear how the molecular signature in the
brain may manifest as behavioral alterations after chronic chemotherapy treatment, as many of
these IEG products largely promotes positive effects on cognition. Alternatively, these increased
levels after treatment could represent early compensatory changes in gene expression that could
precede impending improvements in cognitive functioning over time. These animal studies
concluded after three consecutive weeks of drug administration. It is possible that chemotherapy
–treated animals may exhibit recovery in cognition over a longer period of time (Lee et al., 2006;
Long et al., 2011).
The expression of oxidative stress- responsive genes were analyzed in the hippocampus
and PFc (Figure 2.12, 2.13). The data indicate GPX1, NFkB ,PRDX1, and TNFa levels were
significantly higher in both brain regions after treatment. GPX1 (glutathione peroxidase) is an
intracellular antioxidant enzyme that catalyzes the reduction of hydrogen peroxide (H2O2) by
glutathione to buffer cells against oxidative damage. Similarly, PRDX1 (peroxiredoxin 1) has an
important role in the detoxification of peroxides. Therefore, the upregulation of the antioxidant
defenses indicates a response to oxidative stress induced by systemic treatment with the
combination AC-chemotherapy. Both of the chemotherapy drugs used in the study have been
documented to induce reactive oxygen species in many tissues including the CNS. The
upregulation of the inflammatory cytokine TNFa (Tumor necrosis factor) and transcription
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factor NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) supports published
findings that the alterations in redox status after systemic treatment may be driven by
inflammatory changes that may indirectly induce oxidative stress in the brain (Aluise et al.,
2011;Hayslip et al., 2015). In the hippocampus of AC chemo-treated rats, there was also a noted
decrease in the levels HO-1 (Heme oxygenase-1), an inducible enzyme responsible for the
oxidative cleavage of heme groups to produce biliverdin, carbon monoxide, and ferrous iron. The
levels of catalase, an enzyme that catalyzes the decomposition of hydrogen peroxide to water and
oxygen and thioredoxin, a major cellular protein disulphide reductase that is critical for redox
regulation, were found at significantly higher levels in the PFc of chemotherapy-treated groups.
Furthermore, a decreasing trend in COX-2 levels, an inducible form of cyclooxygenase enzyme,
indicates an overall response to ROS and inflammatory conditions as a result of chemotherapy
treatment.
Considering the evidence that shows that the toxic effects of doxorubicin is mediated
through superoxide anion generation, there were no differences observed in the levels of Cu/Zn
SOD or MnSOD, superoxide dismutase enzymes that are responsible for the conversion of
superoxide to hydrogen peroxide (Fukai et al., 2011). There are technical limitations in
measuring the direct concentrations of reactive oxygen and reactive nitrogen species in tissues,
and have not been addressed in this study. Nevertheless, the indirect measurement of regulatory
molecules implicated in the antioxidant defense and inflammatory response supports that the
neurotoxic effects of AC-chemotherapy is mediated through the generation of oxidative stress.
Mitogen-Activated Protein Kinase (MAPK) signaling is influenced by various cell
stressors. We evaluated the phosphorylation status of the ERK 1/2 and JNK/SAPK pathways in
the hippocampus and PFc . The results of the western blot and immunohistohemical analysis
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demonstrates that ERK signaling was significantly higher in the hippocampus of AC chemotreated animals. Interestingly, the micrographs in Figure 2.14 A indicate that the strong
activation of ERK is found along the mossy fiber pathway, where granule cells of the dentate
gyrus form distinctive unmyelinated axons that project to the Cornu Ammonis area 3 (CA3).
Furthermore, higher levels of JNK/SAPK phosphorylation was also detected after treatment in
the hippocampus along with a modest and insignificant increase in the PFc. It is important to
note that depending on the neuronal cell population, the threshold for stress and the cellular
response can be manifold. For example, in the hippocampus high intrinsic oxidative stress in
glutamatergic CA1 pyramidal neurons make them potentially more vulnerable than CA3 neurons
to excitotoxicity and neurodegeneration (Wang and Michaelis , 2010) .Overall the results
presented in this study suggest that chronic activation of these signaling molecules could be
related to the oxidative stress and inflammatory conditions in the CNS imposed by systemic ACchemotherapy.
The data from the proteome cytokine array demonstrates that the levels of various
proinflammatory cytokines and chemokines are upregulated in hippocampal protein lysates of
chemotherapy- treated animals (Figure 2.17). Among these inflammatory regulators, IL-6 and
TNFa are consistent with the peripheral cytokine biomarkers that have been observed in breast
cancer patients during treatment and in both the plasma and CNS of doxorubicin injected rats
(Aluise et al., 2011; Janelsins et al. 2012, Kessler et al., 2013). Furthermore, the qPCR data
analysis in Figure 2.12 showing an increase in the mRNA levels of TNFa and the transcription
factor NFkB suggests that the activation of a pathway leading to neuroinflammation is
upregulated. A chemokine that is increased in the hippocampus of treated rats include MIG
(Monokine induced by Interferon Gamma) as well as the cytokine responsible for its induction,
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interferon γ (IFN-γ). Robust levels of the Macrophage Inflammatory Protein (MIP) family, MIP1alpha and MIP-3alpha, were also found in this group. These chemokines regulate the
recruitment and induction of pro-inflammatory cytokine release from macrophages and T cells.
The levels of IL-10 and IL1ra were increased, demonstrating that anti-inflammatory mechanisms
are also enacted and could potentially counter the damaging effects associated with a chronic
inflammatory response. Interestingly, the relative levels of VEGF (vascular endothelial cell
growth factor) a secreted factor implicated in angiogenesis and documented to exert
neuroprotective effects in the CNS were also upregulated after treatment (Hao and Rockwell,
2013). The only chemokine in the proteome array panel observed to decrease after chemotherapy
treatment is Thymus chemokine/CXCL7, a potent chemoattractant and activator of neutrophils.
The biological relevance of this relative decline in CXCL7 is not clear considering several other
proinflammatory molecules are upregulated.
The antineoplastic agents used in this study are associated with DNA damage. In
particular, doxorubicin is a redox cycling agent that can increase ROS levels and therefore
induce oxidative damage to nucleic acids as an indirect mechanism. A immuno-northern blot
(INB) protocol from Mishima et al. (2015) was adapted in this study to detect whether these
oxidative RNA modifications would occur in the brain after systemic exposure to AC
chemotherapy. We carried out INB procedures using agarose gel electrophoresis for the
separation of high molecular weight 28S and 18S ribosomal RNA (rRNA). Samples derived
from AC chemotherapy-treated rats have significantly higher levels of oxidized 28S rRNA than
saline controls (Figure 2.19 B). As shown in Figure 2.19 A, stronger anti-8OH(d)G
immunoreactive bands were detected in RNA on the blots corresponding to around 18S and 28S
rRNA and confirmed by methylene blue counterstaining.
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The results of INB using anti-8OH(d)G antibodies were consistent with the findings
obtained by dot blot analysis of unfractionated total RNA, demonstrating that higher signals were
detected in samples derived from the hippocampus of AC-treated rats (Figure 2.18). A growing
number of studies indicate that various RNA species, including ribosomal RNA and messenger
RNA, is vulnerable to oxidative damage and higher levels are found in a number of
neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis and
Parkinson’s disease (Nunomura et al.,2009; Kong and Lin, 2010) . Additionally, these oxidative
modifications to both coding and noncoding RNA have severe consequences on the translational
processes involved in gene expression and the fidelity of the proteins that are produced (Simms
and Zaher, 2016).
In a separate cohort of animals that were injected using the same drug protocol, we
performed immunohistochemical analysis to evaluate the expression and localization of
oxidative damage marker 8-hydroxy(deoxy)guanine (8-OHdG) in the hippocampus. The
representative micrograph in Figure 2.20 A shows that there are sub-field specific differences in
the relative levels of 8OHdG. In particular the CA1 and CA3 regions displayed higher signal
intensities in AC-treated rats relative to saline controls, suggesting increased nucleic acid
oxidative damage (Figure 2.10 B). Furthermore, double immunofluorescence of hippocampal
tissue sections using antibodies specific to NEUN, a protein localized to the nuclei and
perinuclear cytoplasm of mature neurons demonstrate that 8-OH(d)G labeling is restricted to
specific cell types (Figure 2.21). An examination of the hippocampal tissue at a higher
magnification shows that the 8OH(d)G staining patterns are primarily localized to the cytoplasm,
suggesting that RNA or mitochondrial DNA (mtDNA) are targets of these modifications. These
observations are also supported by the findings from the INB experiments with RNA samples
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that were processed with DNAse to remove contaminating genomic DNA. Overall the data
presented in this dissertation from the immunoblot and immunohistochemistry experiments
establishes the first evidence that chemotherapy can induce oxidative damage to cytoplasmic
RNA or potentially mtDNA) in the brain, which might play a role in the pathophysiology of
cognitive impairment after treatment.
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Chapter 3
Cellular Model of Doxorubicin –induced Neurotoxicity in Primary Hippocampal Neurons:
Role of Oxidative Stress and Impaired BDNF Signaling
Abstract:
Doxorubicin is an anthracycline-based cytostatic agent commonly included in the
chemotherapy regimen for the treatment of breast cancer. Accumulating evidence indicates that
several chemotherapeutic agents are associated with persistent deficits in cognitive functioning.
However, anthracyclines such as doxorubicin may have greater negative effects on healthy tissue
than other classes of chemotherapy. The established mechanisms of action by doxorubicin in
cancer cells include the intercalation of DNA, inhibition of topoisomerase enzymes and the
generation free radicals. Although a growing number of in vivo animal studies have started to
examine the various mechanisms implicated in the effects of treatment, the results are often
difficult to interpret given the heterogeneity of the blood –brain barrier and CNS tissue. In the
current study , we examined the effects of transient doxorubicin exposure on the viability of
isolated hippocampal neurons and addressed whether the cytostatic agent interferes with
BDNF-mediated signal transduction and gene expression. Furthermore, we investigated whether
the neurotoxic effects of doxorubicin is associated with the generation of ROS and oxidative
damage. We found that doxorubicin induces cell death , caspase -3 activation and significant
superoxide induction in hippocampal neuron cultures . Additionally, BDNF-mediated signaling
and the activation of protein translation pathways were repressed after doxorubicin exposure .
The upregulation of the immediate early gene arc by BDNF was also impaired in the presence of
doxorubicin , an effect that was partially rescued in neuronal cultures by preincubation with the

75

antioxidant acetyl-l- carnitine. These results suggest that doxorubicin causes neurotoxic effects
on neuronal survival and synaptic plasticity through an oxidative-stress mediated mechanism.
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3.1 Introduction: Doxorubicin –induced neurotoxicity
Our previous studies have shown that chronic exposure to a common chemotherapy
cocktail, cyclophosphamide and Adriamycin (doxorubicin), impairs some forms of hippocampalmediated memory in rats (Salas-Ramirez et al., 2015). Others have also demonstrated that
behavioral alterations in rodents administered doxorubicin alone are associated with enhanced
proinflammatory cytokine production and oxidative damage in the plasma and brain (Joshi et al.,
2005; Tangpong et al., 2006; Tangpong et al., 2011; Joshi et al., 2010; Aluise et al., 2010).
Although the diffusion of doxorubicin into the CNS is profoundly limited by its ability to cross
the BBB, rodent studies uncover a mechanism for the toxic effects of the chemotherapeutic on
brain function.
Oxidative stress and the resulting cellular damage linked to doxorubicin is a major risk
factor for accelerated aging and disease development across many organ systems, including the
CNS. It has been long suspected that doxorubicin and other chemotherapy agents promote
molecular aging (Ahles, 2012; Sanoff et al., 2014). It is unclear whether there are specific areas
of the brain that are more susceptible to the neurotoxic effects of chemotherapy. Deficits in
memory, attention, executive function and processing speed have all been observed in cancer
survivors (Schagen and Wefel, 2013). Functional neuroimaging data have also corroborated
alterations in the activation of hippocampal and prefrontal brain regions with neuropsychological
test performance in these patients. Hippocampal neurons are particularly vulnerable to various
stressors including ROS/RNS ,and age-related dysfunction of cognition could be attributed to
the accumulation of oxidative damage in the brain (Wang and Michealis, 2010). In an in vitro
model, doxorubicin decreases the viability of different primary neuronal cultures in a
concentration and time dependent manner that is also dependent on the developmental stage of
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the neurons (Jantas and Lason, 2009). Additionally, in isolated neuronal cell cultures, the levels
of ROS/RNS are significantly increased by doxorubicin exposure that is also associated with cell
death in a concentration biphasic manner (Lopes et al., 2008; Lopes et al., 2011; MorunoManchon et al., 2018). Recent evidence has also implicated a role for autophagy in the
neurotoxic effects of the drug. In one study, the increased levels of autophagosomes, damaged
mitochondria, and lipid droplets were found in isolated neurons and in the brains of mice injected
with pegylated liposomal doxorubicin (Moruno-Manchon et al., 2016, 2018). Additionally,
lysosomal pH was observed to be higher in neurons exposed to doxorubicin than in vehicletreated neurons. Ultimately it was concluded that doxorubicin was associated with damage to
the autophagy-lysosome system in neurons.
Only a few studies have addressed the in vitro effects of doxorubicin on cellular models
of memory. Doxorubicin was found to attenuate the effects of serotonin on long-term facilitation
(LTF) in sensory neuron- motor neuron co-cultures isolated from the marine mollusk Aplysia
(Liu et al., 2014). In contrast, doxorubicin enhanced long-term depression (LTD) induced by the
neuropeptide Phe-Met-Arg-Phe-NH2 (FMRFa). These effects were also associated with elevated
levels of p-ERK and p-p38 MAPK in the sensory neurons (Liu et al., 2014). A recent study also
found that doxorubicin led to a reduction in the density of synapses and neurites in cultured
primary neurons, an effect partially mitigated by the anti-epileptic drug Levetiracetam (MorunoMancho et al., 2016). The objectives of the current study was to examine whether the induction
of ROS by doxorubicin is a mechanism by which the drug may impair neuronal function by
targeting signaling pathways involved in the translational control of synaptic plasticity.
The interference of brain-derived neurotrophic factor (BDNF)-mediated signal
transduction may underlie some of the cognitive deficits associated with chemotherapy (Ng et
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al., 2017). Increasing studies demonstrate the requirement for de novo gene expression during
memory consolidation. Moreover, BDNF plays an essential role in the activity-dependent
modification of excitatory synapses through the up regulation of local protein synthesis (Takei et
al., 2004; Tang et al., 2002; Santos et al., 2010). Neuronal mRNAs that are translated in response
to BDNF stimulation have been characterized and many encode proteins implicated in synaptic
function including Arc, CaMKII, Homer, and glutamate receptor subunits (Schratt et al., 2004;
Slipczuk et al., 2009). Furthermore, the BDNF-regulated translation of this subset requires
activation of the mammalian target of rapamycin signaling pathway (mTOR). Conditions that
perturb BDNF signaling may also interfere with downstream mechanisms involved in synaptic
plasticity and the translation of specific mRNA molecules. Recent studies showed that neural
cells exposed to a chronic mild oxidative stress paradigm exhibited decreased responsiveness to
BDNF and recapitulated several aspects of the aging process (Chadwick et al., 2010). The
interactions of oxidative stress, neurotrophin signaling and protein homeostasis is thought to
contribute to the vulnerability of cognitive functions during aging and may underlie various
pathological conditions.
3.1.1 Synaptic plasticity
Synaptic plasticity refers to the intrinsic or extrinsic changes in synapse strength and is
thought to underlie learning and memory formation in the brain (Mayford et al., 2012).
Furthermore, these changes in the efficacy of neurotransmission are also accompanied by
alterations in the synaptic structure (Meyer et al., 2014). Multiple mechanisms contribute to the
many different forms of synaptic plasticity and have been studied extensively (Citri and
Malenka, 2008). In particular, long term potentiation (LTP) and long-term depression (LTD),
which refer to persistent increases or decreases in synaptic strength, respectfully, are proposed to

79

be the cellular basis of memory (Malenka and Bear, 2004). LTP is temporally divided into an
early and late phase, with the latter phase requiring new protein synthesis (Frey and Morris,
1997). Pioneering studies of learning in Aplysia, as well as in other invertebrates and vertebrates,
have revealed that changes in gene expression are required to convert short-term facilitation (or
short term memory) to long-term facilitation (long term memory, LTM) (Kandel, 2001). In the
mammalian brain, the application of pharmacological inhibitors of both transcription and
translation impairs LTP at hippocampal synapses normally induced by tetanic stimulation
(Vickers et al., 2005; Klann and Dever, 2004). Therefore, this requirement for new protein
synthesis is a key feature that is shared between LTP and long-term memory consolidation. The
presence of translational machinery components in specialized dendritic compartments called
spines have supported an essential role for local mRNA translation in synaptic function
(Steward, 1983; Tang and Schuman, 2002) . Several mRNA species are targeted to the dendrites
via RNA-binding proteins and are potentially translated in response to neuronal activity (Martin
and Zukin, 2006). Microarray analysis have identified several localized transcripts that encode
proteins that are involved in translational regulation (Poon et al., 2006). Taken together, these
studies indicate that local changes in the synaptic proteome may contribute to the long-term
changes in synaptic plasticity.
3.1.2 BDNF and Synaptic Plasticity
Dendritic protein synthesis in hippocampal neurons is triggered in response to activity
and is necessary for certain forms of synaptic plasticity (Vickers et al., 2005; Kang and
Schuman, 1996; Huber et al.,2000). Of particular interest to the proposed studies is the
neuromodulatory effects of brain-derived neurotrophic factor (BDNF). BDNF is secreted in
response to synaptic activity and is a key regulator of the long lasting structural and functional
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changes that underlie long term memory. Studies have demonstrated that mice with deficient
BDNF or the cognate receptor TrkB, exhibit impaired L-LTP and decreased performance on
learning tasks (Lu et al., 2008; Minichiello et al. 1999). Furthermore, the acute application of
BDNF induces a long-lasting potentiation of synaptic transmission in hippocampal slices that is
dependent on novel protein synthesis (Leal et al., 2014; Ji et al., 2010). BDNF regulates synaptic
consolidation through the rapid induction of Arc mRNA translation, an effector immediate early
gene that is known to directly affect neuronal function (Yin et al., 2002). Newly synthesized Arc
is necessary for the phosphorylation of the actin- associated protein cofilin and the remodeling of
dendritic spines during LTP processes (Messaoudi et al., 2007). Others have also demonstrated
the upregulation of Arc and other synaptic proteins in vivo, including BDNF, after hippocampal dependent learning ( Panja et al., 2009; Soule et al., 2008; Guzowki et al., 2000).
3.1.3 BDNF/Trk B Signaling
The cellular responses of BDNF are mediated by activation of the tropomyosin-related
kinase B (TrkB) receptor. Upon ligand binding, the full length TrkB receptor dimerizes and the
tyrosine residues in the intracellular domain undergo autophosphorylation (Minichiello, 2009).
These changes lead to phosphorylation of tyrosine residues within the carboxyl terminus to
facilitate the recruitment of adaptor molecules to docking sites on the receptor (Kaplan and
Miller, 2000). There are multiple intracellular signaling pathways that can be activated in parallel
by BDNF including the phospholipase C- g pathway, the Ras/Erk (extracellular regulated kinase)
pathway, and the PI3-K (phosphatidylinositol 3-kinase) /Akt/mTOR (mammalian target of
rapamycin) pathway. The phosphorylation site on Tyr516 of TrkB recruits and facilitates the
interaction between Shc and Grb2 adaptors to regulate the Ras/MAPK and PI3K/Akt pathways
(Huang and Reichardt , 2003). BDNF-TrkB signaling activates the PI3-K cascade through
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different mechanisms (Minichiello, 2009). While the activation by the GTPase Ras plays a
critical role in promoting neuronal survival, additional adaptor proteins are recruited to the
receptor to mediate other functions downstream of PI3K. In particular insulin receptor-substrate
(IRS-1/2) is also a major substrate of TrkB that couples the receptor to intracellular signaling
cascades. IRS-1 contains several SH2 (Src homology 2) sites that mediates the direct binding and
subsequent activation of the p85 regulatory subunit of PI3- Kinase (Korhonen et al., 1999). The
generation of phosphorylated 3-phosphoinositides by PI3-K together with 3-phosphoinositidedependent protein kinases (PDPK) activates Akt (also known as protein kinase B). In turn, Akt
can phosphorylate many targets to trigger pleiotropic effects in neurons, such as cell survival and
protein translation (Figure 3.1; Costa-Mattioli and Monteggia, 2013).
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Figure 3.1: Regulation of the mTOR signaling pathway and translational control in
the brain. Adapted from Costa-Mattioli and Monteggia, 2013
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3.1.4 Regulation of mTOR Signaling
The serine/threonine kinase mTOR (mammalian target of rapamycin) is an important
regulator of protein translation in eukaryotic cells and is required for several protein-synthesis
dependent forms of synaptic plasticity, including those mediated by BDNF (Kang and Schuman,
1996; Slipczuk et al., 2009). mTOR plays a central role in the regulation of dendritic arborization
and spine morphology. The coordinated activation of mTOR with the Ras/MAPK signaling
pathway, are responsible for neurotrophin-dependent structural plasticity (Kumar et al., 2005).
Akt activates the mTORC complex through the phosphorylation and inhibition of TSC (tuberous
sclerosis complex), a negative regulator of mTOR signaling. Alternatively, the Erk/MAPK
pathway is capable of regulating mTOR through the direct phosphorylation of TSC or indirectly
via RSK (90 kDa ribosomal S6 kinase) (Mendoza et al., 2011). In mammalian cells mTOR
functions in two distinct complexes; mTORC1 and mTORC2. As part of the rapamycin-sensitive
complex (mTORC1), mTOR interacts with the scaffolding molecule Raptor, which binds the
downstream effectors 4E-BP1 and S6K. On the other hand, the rapamycin -insensitive protein
complex (mTORC2), is responsible for the direct phosphorylation and full activation of Akt
(Sarbassov et al., 2005). The major targets of the PI3K/AKT/mTORC1 signaling cascade are
components of the translational machinery (Gingras et al., 2001; Figure 3.1).
3.1.5 mTOR signaling in plasticity and memory
The discovery of the potent immunosuppressant rapamycin has yielded considerable
insight into the functional role of mTOR in protein translation and synaptic plasticity (Hoeffer
and Klann, 2010). Rapamycin prevents the association between mTOR and Raptor, thereby
interrupting the ability of mTORC1 to phosphorylate its substrates. The evidence demonstrating
the role of mTOR translational signaling in synaptic plasticity in the mammalian brain derived
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from studies of late-phase long-term potentiation (l-LTP) in the rodent hippocampus. The
application of rapamycin resulted in a reduction of late-phase LTP expression induced by highfrequency stimulation and blocks BDNF-mediated synaptic potentiation in hippocampal slices
(Tang et al., 2002; Cammalleri et al., 2003). In other brain regions, the induction of LTP triggers
the activation of mTOR and downstream signaling targets in a rapamycin -sensitive manner (Sui
at al., 2008). The targeted infusion of rapamycin into the rodent hippocampus after training was
also shown to impair long-term spatial memory (Dash et al., 2006). Taken together, the evidence
suggests that mTOR plays a crucial role in memory formation through the regulation of protein
synthesis.
3.1.6 Translational Control Mechanisms: Initiation
The control of cap-dependent translation requires the association of the eukaryotic
initiation factor (eIF) 4F complex with the modified guanosine cap structure on the 5’ end of
messenger RNAs to facilitate the recruitment of the 40S ribosomal subunit. The cap-binding
protein within this complex is eIF4E and acts in the rate limiting step of translation initiation
during protein synthesis. Translation is a highly regulated in part through eIF4E inhibitory
proteins termed 4E-BPs. Activated 4E-BPs repress translation by sequestering eIF4E and
inhibiting protein -complex assembly on mRNA. mTORC1 signaling removes this repression
through the phosphorylation of 4E-BP1 which decreases the binding affinity for eIF4E (Hay and
Sonenberg, 2004). The other target of mTOR are the ribosomal protein S6 kinases and are
implicated in the control of cell growth through enhanced translation (Hoeffer and Klann , 2010).
Activated S6K and its substrate S6 increases the translation of 5’TOP (terminal oligopyrimidine
tract) mRNAs that encode components of the biosynthesis machinery, including elongation
factors and ribosomal proteins.
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As discussed previously, the control of mRNA translation in neurons has emerged as a
critical process implicated in learning and memory. However, it is not clear how the mechanisms
that mediate protein synthesis during synaptic plasticity are regulated under oxidative stress
conditions. The age or pathology -related increase in the levels of brain oxidants contributes to
synaptic dysfunction and memory impairment. We hope to characterize the pharmacological
effects of the free radical generator doxorubicin on BDNF signaling in primary hippocampal
neurons as a cellular model of chemotherapy-related cognitive impairment. We postulate that
alterations in BDNF-mediated protein translation after oxidant exposure may underlie some of
the cognitive deficits associated with doxorubicin.
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3.2 Methods: Cellular Model of Doxorubicin –Induced Neurotoxicity
Primary Hippocampal Neuron Culture Preparations
All experiments were conducted according to protocols approved by the lnstitutional Animal
Care and Use Committee at The City College of New York. Primary hippocampal neurons will
be obtained from early postnatal P0 Sprague Dawley rat pups (Charles River Laboratories) for
neurotoxicological studies using a modification of a previously described procedure (Brewer et
al. 1993). Briefly, 1 day postnatal rat pups from timed pregnant dams will be sacrificed by
decapitation. Hippocampi will be aseptically isolated and dissected in ice cold Ca2+ -Mg2+ free
Hanks Balanced Salt Solution (HBSS, Invitrogen, Life Technologies) . After removal of the
meninges, the tissue will be digested in 0.25% trypsin for 15 minutes in a 37C water bath. After
rinsing in prewarmed HBSS, tissue will be resuspended in DMEM/ 10 %FBS/DNase and
triturated with a fire polished Pasteur pipette. Dissociated tissue will be filtered through a 40µm
mesh strainer. Isolated cells will be plated into poly –D-lysine (100 µg/ml) coated plates as
follows: 96-well plates (3× 10 cells/well) for viability studies, 6-well plates (5 × 10 cells/well)
4

5

for Western blot analyses, 8-well chamber slides (1 × 10 cells/well) for immunofluoresence
5

staining, and uncoated T75 flasks for glial cell cultures. After about 4 hours or when most cells
adhere to plate, medium will be replaced with Neurobasal (Invitrogen/Life Technologies)
medium, L-glutamine (GlutaMAX Invitrogen/Life Technologies), and penicillin + streptomycin
(antibiotic–antimycotic; Invitrogen/Life Technologies) supplemented with B27. Cytosine
arabinoside (AraC) will also be added to cultures to inhibit the proliferation of glial cells. On day
4, half of medium will be removed and replaced with a glial conditioned medium (GCM).
Cultures will be maintained in Neurobasal-B27/GCM (1/1 ratio) for 13 days in vitro by replacing
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half of the medium every 3-4 days. Neuronal purity of the cultures was evaluated occasionally
using staining with astrocytic marker GFAP.
Pharmacological treatments
The effects of cyclophosphamide and doxorubicin (LKT laboratories) were evaluated in the
neuronal cultures to assess the role of the chemotherapeutic agents. About 1 hour before
treatments, the media was switched to serum –free complete media containing Neurobasal B27
minus antioxidants (B27 –AO, which lacks superoxide dismutase, catalase, etc) in order to
examine the role. Hippocampal cells were treated at concentrations of 0.1µM to 1µM
doxorubicin and/or cyclophosphamide (LKT laboratories) prepared in sterile water. The
concentrations assessed in these studied are based on preliminary experiments and from
previously published studies (Lopes et al., 2008; Sardi et al., 2013). Cells were exposed to the
respective drugs for 6, 24 or 48 hours. Additionally, some cells were pretreated with the
antioxidants 100 µM of Acetyl L Carnitine (Sigma), before exposing to the chemotherapy drugs.
Recombinant BDNF (Peprotech) was used in some experiments to simulate neurotrophin mediated synaptic plasticity in the neuronal cultures. After drug treatments, cells were exposed
to either BDNF (30ng/ml) or vehicle for 1 hour and then processed for either immunocytochemical or biochemical analysis.
Cell viability
MTS cell viability assay
The neurons were plated in the 96 well culture plates and exposed to the various concentrations
of the chemotherapy agents at different time points as described previously to examine the effect
of these drugs on cell viability using the The CellTiter 96® AQueous kit (Promega). In viable
cells MTS tetrazolium is reduced to a colored formazan compound in culture. These reagents are
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also optimized for direct use in cell culture medium. In viable cells the reducing agents NADH
or NADPH pass their electrons to an intermediate electron transfer reagent that can reduce MTS
into the aqueous, formazan product. However compromised cells undergoing cell death have
decreased ability to reduce tetrazolium products. The production of the colored formazan product
is an index for the number of viable cells in culture (Riss et al., 2016). Briefly, a reagent is added
directly to the assay wells at a recommended ratio of 20µl reagent to 100µl of culture medium.
Neurons are incubated 2 hours at 37°C, and then absorbance is measured at 490nm using a plate
reader.
Fluorescence microscopy-based viability assay and Caspase Detection
Neuronal survival after exposure to the various neurotoxic insults were evaluated using
ReadyProbes Cell Viability Imaging Kit, Blue/Green (ThermoFisher Scientific) according to
manufacturer’s instructions. These viability probes consist of a NucBlue® Live reagent which
stains the nuclei of all cells and a NucGreen® Dead reagent that stains only the nuclei of dead
cells with compromised plasma membranes. Alternatively, the detection of apoptotic cells was
performed using the CellEvent™ Caspase 3/7 Green Detection Reagent (Life Technologies).
Briefly, parallel cultures of neurons were seeded onto 8 –well chamber slides and subjected to
the conditions described previously. After treatment, 50 µl of each of the ReadyProbes or
CellEvent reagents were added directly to wells and incubated for 15 minutes .Images of stained
cells were taken by confocal microscopy using a Zeiss LSM 710 confocal microscope with 10x
objective.
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ROS Measurement
Doxorubicin-induced intracellular generation of ROS was measured by monitoring the
oxidation of the cell-permeable CellROX Deep Red Reagent (Molecular Probes, Carlsbad, CA).
An advantage of using the CellROX reagent over more standard fluorescent probes like 2’,7’dichlorofluorescein (DCF) is that, upon oxidation the probe exhibits a strong fluorescent signal
that is stable after paraformaldehyde fixation. Briefly, neurons plated onto 8 well chamber slides
or in 96 well plates were switched to B27 –AO medium (AO; antioxidant-free) and then exposed
to various concentrations of doxorubicin for 6 hours. Subsequently, cells were incubated with 5
µM CellROX Deep Red Oxidative Stress Reagent for 30 min at 37˚C and, after three washes
with PBS, were fixed for 10 min in 4% paraformaldehyde. Cells were mounted and coverslipped with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher).
Mitochondrial superoxide formation was detected by fluorescence microscopy using
MitoSOX™ Red as a specific fluorescent probe. Neurons were subjected to the conditions
described previously and were incubated with 5 μM of the probe for 30 min at 37°C in dark. The
cells were then washed thoroughly with warm Hank's Buffered Salt Solution (HBSS) buffer and
mounted for imaging. Fluorescence was analyzed using a confocal laser scanning microscope
(LSM710; Zeiss) Images were subsequently analyzed with ImageJ software.
Protein extraction, SDS-PAGE, and Western blotting
After the treatments, neurons were harvested for total protein. The medium was aspirated from
cultures followed by washes in ice-cold PBS to remove residual medium. Neurons were lysed in
ice-cold NP-40 buffer (40 mM Tris–HCl pH 7.5, 274 mM NaCl, 2 mM EGTA, 20% v/v
glycerol, 50 mM NaF, 1 mM Na3VO4, 1 mM -glycerol phosphate, 1 mM PMSF, 2.5 mM
sodium pyrophosphate, 1% NP-40, and protease inhibitor cocktail (Thermo scientific) and
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clarified by centrifugation at 14,000 x g for 15 min at 4 C. Protein concentrations were
o

determined using the micro BCA protein essay (Pierce).
Thirty micrograms of protein from experiments either using primary hippocampal neurons or
hippocampal tissue from in vivo treatments were electrophoretically separated by 10% SDS
PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred onto a PVDF
membrane (Immobilon-P, Millipore). The membranes were blocked in 5% nonfat dry milk for
one hour at room temperature and subsequently incubated with specific primary antibodies
overnight at 4°C. Following several washes, membranes were incubated for one hour with the
appropriate Horse Radish Peroxidase (HRP)- conjugated secondary antibodies. The immune
complexes were detected by the enhanced chemilluminescence (ECL) detection system (GE)
and signal intensities were quantified by Image J using b actin as a loading control.
Alternatively, protein expression was analyzed using the Near –Infrared Odyssey detection
(LiCOR). After electrophoretic transfer of proteins to Immobilon-FL (low auto fluorescence)
PVDF membranes (Millipore), membranes were blocked followed by incubation with primary
antibodies in Odyssey Blocking buffer. After washing, membranes were incubated with the
appropriate IR-700 or IR800 dye secondary antibodies (LiCOR) for one hour. Signals were
quantitated using the Li-COR Image Studio Software.
RNA Isolation, Reverse Transcription and qPCR
Total RNA was extracted using Tri-Reagent (Sigma) according to manufacturer’s instructions.
Reagents were added directly to cell culture plates, scraped and transferred to micro centrifuge
tubes. The RNA was extracted in the phenol-chloroform solutions, precipitated in isopropanol
and the pellet was washed in 75% ethanol before being resuspended in nuclease-free water. RNA
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was treated with DNASE I to remove any contaminating genomic DNA. RNA concentration and
quality was assessed using the NanoDrop spectrophotometer as described previously. Reverse
transcription was carried out using the Verso cDNA synthesis kit and quantitative realtime PCR
was carried out on the Applied Biosystems 7500 Real-Time PCR System using PowerUp
SYBR® Mix (Life Technologies). Each sample was run in triplicate and in a total volume of
20 μL. Fold change in expression for each gene was normalized to the expression of β actin, the
reference gene and calculated by a comparative threshold cycle ( Ct ) method . Primer sequences
are shown in Table 2.
Immunofluorescence Staining
Neurons were cultured in chamber slides and treated as described above. Cells were then fixed in
3.7% paraformaldehyde for 15 min, permeabilized with 0.1% saponin for 15 min and blocked
with 1% BSA in PBS with 0.25% Tween 20 for 30 min. Cells were incubated overnight with
primary antibodies in blocking buffer at 4C. Antigen detection was performed using Alexa Fluor
488, Alexa Fluor 594, or Alexa Fluor 633 conjugated secondary antibodies (Invitrogen). Slide
were coverslipped with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher) and
images were captured using Zeiss 710 Laser Scanning Confocal Microscope.
Statistical Analysis
Results are reported as mean± S.E.M. Data were analyzed using either Excel (Microsoft) or
Graph Pad Prism 5 Statistical Software. Analyses were performed on at least three independent
biological replicates by either Student’s t test, to compare means of two treatment groups, or if
suitable , by analysis of variance (ANOVA) followed by post hoc Fisher’s test for pairwise
comparisons. Statistical significance was accepted at p values less than 0.05.
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Chapter 3.3 Results
3.3.1 The Effects of Doxorubicin on the Metabolic Activity and Viability of Primary
Hippocampal Neurons
The objective of this experiment was to evaluate the effects of chemotherapeutic agents
on the metabolic activity and cell viability of isolated hippocampal neurons. As described in the
Methods, hippocampal neurons were plated onto 96-well poly d lysine coated plates and
maintained in Neurobasal-B27 medium for 13 days. Hippocampal cells were treated with various
concentrations of 0.1µM to 1µM doxorubicin and/or cyclophosphamide at different exposure
times (6h,24h,48h). Metabolic activity of hippocampal neurons was assessed using the CellTiter
96® Aqueous MTS kit (Promega). As shown in Figure 3.2 significant decrease in viability was
observed at 0.1 µM (67%) 0.25 µM (43%), and 1 µM (48%) doxorubicin (t=48 hours) (panel C)
; 0.5 µM cyclophosphamide (56% t=24hr, 55% t=48hr) (panel A); and 1µM cyclo/dox combo
(65%, t=24 hour) (panel B) relative to controls. General but statistically insignificant decreases
were also found across the other Dox-treated groups , especially at longer time exposures . A
surprising increase in the metabolic activity was also observed in hippocampal neurons treated
for 6 hours with 0.1 µM cyclophosphamide (173% of control, panel A).
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Tetrazolium reduction in cells reflect cellular metabolism -mediated primarily through
mitochondria, as a result there are several limitations when using MTS/MTT –based assays as a
measurement of viability (Riss et al., 2016). An alternative approach using fluorescent probes
were employed to examine the effects of doxorubicin (0.25 µM and 0.5µM, t=6hr). Neuronal
survival after exposure to doxorubicin were evaluated using ReadyProbes Cell Viability
Imaging Kit, Blue/Green (ThermoFisher Scientific). Doxorubicin induces significant cell death
in neurons (Figure 3.3A). This was evidenced by 67+ 7% Nucgreen Dead positive cells at 0.25
µM concentration of Dox and 82+ 12% positive cells at .5µM Dox compared to 21+ 7% in
untreated controls.
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The detection of apoptotic cells was also performed using the CellEvent™ Caspase 3/7
Green Detection Reagent (Life Technologies) or assessed by western blotting using an antibody
that detects the cleaved form of Caspase 3. Doxorubicin exposure was associated with significant
fluorescence, indicating higher caspase 3/7 activities in treated neurons; 30%(0.25 µM Dox) and
56% (0.5µM Dox) increase over control (Figure 3.3 B). Furthermore, a significant increase in
the expression of cleaved caspase 3 protein was also observed at 0.25, 0.5 and 1µM Doxorubicin
relative to untreated neurons (p<0.05, Figure 3.3 C).
3.3.2 Generation of ROS in neurons after doxorubicin exposure
To examine whether doxorubicin generates reactive oxygen species (ROS) in vitro,
hippocampal neurons were isolated and maintained as described previously. Before drug
treatments, media was switched to serum –free complete media containing Neurobasal B27
minus antioxidants (B27 –AO). Mitochondrial superoxide formation was detected by
fluorescence microscopy using MitoSOX™ Red as a specific fluorescent probe. Mitosox
fluorescence increased significantly in neurons treated with 0.25 µM (p<0.05) and 0.5µM
(p<0.01) doxorubicin (Figure 3.4).
Another approach was employed to evaluate the induction general oxidative stress and
the efficacy of antioxidants in doxorubicin treated neurons. As described previously, neurons
plated onto 8 well chamber slides were switched to B27 –AO medium (AO; antioxidant-free)
and then exposed to 0.25 µM doxorubicin for 6 hours. and subsequently incubated with 5 µM
CellROX Deep Red Reagent. As shown in Figure 3.5, a 0.25 µM exposure of doxorubicin led to
a 3-fold increase in CellRox signal intensities (* p<0.05, compared to control). This significant
increase in ROS levels by 0.25 µM Dox was mitigated by the pretreatment of neurons with 100
µM of Acetyl-L-Carnitine (# p<0.05, compared to Dox).
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It is known that doxorubicin intercalates DNA and induces double strand breaks as a mechanism
of toxicity. The results from the oxidative stress experiments also demonstrate that Dox
fluorescence localizes to the nucleus of treated hippocampal neurons (Figure 3.5 A). Given the
significant induction of ROS after Dox exposure, it is expected that there would be damage
inflicted on cellular macromolecules. We examined oxidative damage to nucleic acids by
performing immunohistochemistry with a monoclonal antibody that recognizes 8hydroxyguanosine (RNA) and 8-hydroxy,2-deoxyguanosine (DNA). As shown in Figure 3.6,
intense fluorescence signals are observed in doxorubicin (0.25µM) treated neurons. The punctate
pattern of intense 8-OH(d)G staining in the cytoplasm is clearly seen in the magnified image
presented in Figure 3.6 B.
Vehicle

A.

8 OHdG

.25 µM Dox

B.

8 OHdG

MAP2

8 OHdG

.25 µM Dox

Figure 3.6: A. Doxorubicin induces oxidative damage to nucleic acids in hippocampal
neurons. Images of double immunofluorescence staining of MAP2 (red) and 8 OHdG
(green ) with DAPI counterstain ( blue). Immunocytochemistry showed an increase in 8
OHdG (green) expression in cells after Dox exposure. B. 400x magnification
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3.3.3 The effects of doxorubicin on BDNF- signaling in primary hippocampal neurons.
As described previously, the interference of brain-derived neurotrophic factor (BDNF)mediated signal transduction may underlie some of the cognitive deficits associated with
doxorubicin. We used western blotting to evaluate the effects of doxorubicin on BDNF
signaling in primary hippocampal neurons. The biological functions of BDNF are mediated by
the TrkB receptor. As expected, BDNF induces significant phosphorylation of the TrkB receptor,
and this effect was unaffected by doxorubicin pre-treatment (* p<0.05; 3.7 A and D). Therefore,
doxorubicin does not appear to affect the activation of the receptor by BDNF. BDNF-TrkB
signal transduction activates the MAPK and phosphatidylinositol-3 kinase/Akt pathways.
Surprisingly, doxorubicin did not measurably affect basal Akt phosphorylation (ser473) in
neurons although viability was compromised in the cells after drug treatment (Figure 3.3).
However, the significant activation of Akt observed after BDNF stimulation was not observed in
Dox –treated neurons exposed to the neurotrophin (Figure 3.7 B and E). BDNF -treated and Dox
only groups exhibited significantly increased the levels of phosphorylated ERK 1/2 MAPK in the
hippocampal neurons relative to non-treated controls (Figure 3.7 C and F). Dox/BDNF
combination treatment also significantly increased the levels of phosphorylated ERK 1/2 in
comparison to Dox-only groups. The induction of phospho-ERK in neuronal cultures after
doxorubicin exposure have been reported previously (Lui et al., 2014). The activation of ERK in
this context may be associated with the increased caspase-3 levels measured in the hippocampal
neurons after Dox exposure and suggests a mechanism leading to apoptosis in these cells. These
pleiotropic effects of ERK/MAPK signaling on cell survival likely diverge from the common
neuroprotective effects of pathway activation when recruited by BDNF-TrkB signaling (Atwal et
al., 2000).
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Figure 3.7: Dox pretreatment affected BDNF-induced Akt phosphorylation (B, E)
and activates ERK/MAPK in the absence of the neurotrophin (C,F). No effects of
Dox observed on TrkB phosphorylation (A, D). *p<0.05, compared to control;
#p<0.05 compared to Dox. ANOVA followed by the LSD post hoc Fisher's test.
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We further examined the phosphorylation status of downstream signaling proteins implicated in
the translational control of protein synthesis. BDNF treatment significantly induces the activation
of proteins implicated in translation initiation. The phosphorylated levels of 4EBP1 (B, G),
EIF4e (D, H), S6K (C, I), and r S6 (E, J) were all significantly higher in BDNF stimulated, cells
that were not treated with the chemotherapy drug (* p<0.05, relative to untreated control group;
Figure 3.8). The effects of BDNF signaling on these regulatory proteins of the translational
machinery was attenuated in hippocampal neurons pretreated with Dox († p<0.05, relative to
BDNF group). Significant effects of doxorubicin on the basal phosphorylation levels (in the
absence of BDNF) were also noted for some of the proteins (mTOR, 4EBP1, S6K, and rS6) in
comparison to untreated controls (*p< 0.05). These results reveal that Dox interrupts the
mTORC signaling pathway that could be involved in BDNF-induced translational regulation in
cultured hippocampal neurons.
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3.3.4 Doxorubicin induces induction of immediate early gene Arc by BDNF
Recent studies have shown that doxorubicin disrupts synaptic plasticity in neuronal cells
(Liu et al 2014; Moruno-Mancho et al., 2016). We hypothesize that the inductive effects of
BDNF on plasticity-related gene expression would be impaired under doxorubicin exposure.
Using several approaches, we evaluated the mRNA and protein levels of the immediate early
gene product, Activity-regulated cytoskeleton-associated protein (Arc/Arg3.1) in the
hippocampal neurons. Western blot analysis indicates that the significant induction of arc protein
exhibited after BDNF stimulation, is completely suppressed in cells pretreated with doxorubicin
(Figure 3.9 A, B). This effect is also demonstrated in the immunofluorescence experiments
where the intense labeling of arc is observed BDNF -stimulated neurons, but not in Dox exposed
cells (Figure 3.9 D). Dox auto fluorescence was also observed in the nuclei of treated neurons
demonstrating that the chemotherapeutic agent is stably incorporated in DNA (Figure 3.9 D; red
channel). q-PCR was carried out to examine the mRNA expression of arc. Interestingly,
significant increases in arc levels were detected in the BDNF, Dox-only and Dox-BDNF groups,
relative to untreated controls (Figure 3.9 C, p<0.05). These results may indicate either post –
transcriptional or translational mechanisms may be responsible for the effects of doxorubicin on
neurotrophin –mediated gene expression, notably on the protein expression of synaptic plasticityrelated molecules.
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3.3.5 The effects of doxorubicin on BDNF-induced gene expression is mediated partly through
oxidative stress.
An experiment was conducted to address whether the consequences of doxorubicin on
BDNF-induced arc protein expression related to the ROS-inducing characteristics if the
cytostatic agent. Hippocampal neurons were prepared as described previously. Prior to
doxorubicin exposure, some cells were pre-treated with the antioxidant ALCAR for 1 hour.
Neurons were exposed to 0.25 µM doxorubicin for the indicated time point (t=6 hr) and pulsed
with BDNF for 1 hr. Cells were harvested and total protein was extracted. Western blot analysis
was performed to evaluate the levels of arc. As demonstrated in the previous experiment (Figure
3.9), doxorubicin (Dox-only) exhibited no effects on basal arc protein levels, but attenuated its
induction after BDNF exposure. This effect was partially reversed in neurons pre-treated with
ALCAR, demonstrating a lower but significant magnitude of arc induction in Dox-BDNF groups
(Figure 3.10 ,#p<0.05 relative to Dox-only group). Interestingly, ALCAR treatment appeared to
induce arc protein expression in the absence of the neurotrophin in untreated controls and Dox
groups. Therefore, the induction of arc protein may also be mediated through some other
mechanism, independent of BDNF, although this has not been addressed in these studies.
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Chapter 3.4 Discussion
An inquiry of the factors contributing to cognitive impairment after chemotherapy have
been established through a growing number of longitudinal clinical studies and invaluable in vivo
animal models which have facilitated our understanding of the mechanisms underlying this
condition. Many questions about cognitive dysfunction after cancer treatment still remain. In
vitro cell models of CRCI are beginning to identify specific cellular pathways and the neural
populations at most risk for neurotoxic damage. We found a dose dependent decrease in the
viability of cells exposed to cyclophosphamide (Figure 3.2 A). In contrast, significant decreases
in viability was observed at longer exposures (48h) to doxorubicin according to the MTT assay,
although insignificant decreases in cell viability were found across most Dox groups at all time
points (Figure 3.2 C). This study shows that nanomolar concentrations of cyclophosphamide and
doxorubicin are capable of reducing the metabolic activity and viability of purified hippocampal
neurons. These findings are supported by the earlier studies of Dietrich et al. (2006), that
suggested that the dosages of chemotherapy capable of inducing neuronal cell death were
considerably lower than dosages effectively used to induce toxic effects in tumor cells. The
blood brain barrier (BBB) also restricts the transport of chemotherapeutic agents like
doxorubicin into the brain although genetic polymorphisms in these BBB drug transporters have
been suggested to influence to dosage of the cytotoxic agent that could be delivered to the brain
(Ahles and Saykin, 2007).
The concentration of doxorubicin that we used to investigate the role of oxidative stress
and biochemical changes in neuronal functioning was 0.25 µM, which corresponds to the
approximate amount of doxorubicin quantified in the brain of rats after a single intraperitoneal
injection of the chemotherapy drug (Sardi et al., 2013). At this Dox concentration, neuronal cells
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exhibited a significant increase in cell death that is associated caspase-3 activation (Figure 3.3).
These results are consistent with previous findings that concentrations up to 0.5 µM follow an
apoptotic pattern of cell death, whereas higher concentrations of Dox lead to necrosis in neurons
(Lopes et al., 2008).
A mechanism for the toxic effects of doxorubicin are related to the ability of the
chemotherapeutic agent to generate free radicals. Higher signal intensities of the DNA/RNA
oxidative damage marker 8-OH(d)G was observed in neurons after treatment (Figure 3.6). We
also found that Dox increased the overall levels of ROS and superoxide anions, that were
detected in the cytoplasm and neurites of the hippocampal neurons (Figure 3.4; 3.5).
Furthermore, ROS signals were mitigated in the cells by pre-exposure to the antioxidant acetyl-lcarnitine (ALCAR). Long term dietary administration of a range of pharmacological agents such
as ALCAR, N-acetylcysteine and plant flavonoids have been utilized as strategies for reducing
ROS production and slowing the onset of age related cognitive deficits (Liu et al., 2002; Long et
al., 2009). It is of interest to employ these compounds as potential dietary interventions for
preventing cognitive impairment following cancer treatment.
This study also investigated the consequences of Dox exposure to the neuronal signaling
pathways linking BDNF to the regulation of plasticity related genes. BDNF has been
demonstrated in cell models and in vivo to induce the expression of arc, a protein required for
consolidation of synaptic plasticity and the formation of long-term memory. We established that
induction of Akt activation in neurons by BDNF was significantly reduced by Dox exposure
(Figure 3.7). Dox was also found to increase ERK/MAPK phosphorylation in neurons in the
absence of the neurotrophin. The activation of the MAPKs in neurons after Dox exposure was
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reported by other groups, and may be related to the induction of pathways that could impair
synaptic functioning and the formation of long-term memory (Liu et al., 2014).
Brain-derived neurotrophic factor induces mammalian target of rapamycin (mTORC1) dependent activation of the translation machinery and protein synthesis of various plasticityrelated molecules, including arc (Yoshii and Constantine-Paton, 2010). Our results demonstrate a
significant suppression of mTORC1 signaling in neurons exposed to Dox. Specifically, the
activation of components implicated in canonical cap-dependent translation and the ribosomal
proteins that specifically associate with 5ʹ terminal oligo pyrimidine (TOP) tract containing
mRNAs were impaired by Dox in the absence and presence of BDNF (Figure 3.8). Doxorubicin
has been shown to reduce protein synthesis in tumor cell lines and in models of skeletal muscle
wasting and cardiotoxicity (Nissinen et al., 2016). We observed that the BDNF dependent
upregulation of arc protein, but not mRNA expression is inhibited by Dox (Figure 3.9). This loss
of arc expression was not apparent at the level of mRNA and indicates that Dox is associated
with the downregulation of the translational control machinery or possibly an increase in protein
degradation. Biochemical changes to translation and protein turnover is a common proteome
response to oxidative stress and other adverse stimuli (Vogel et al., 2011). Interestingly, the
administration of Dox also increased arc mRNA in the absence of BDNF, suggesting that the
transcriptional mechanisms related to the effects of chemotherapeutic agent are independent of
the consequences on protein synthesis.
Finally, we demonstrate that the inhibitory effects of Dox on BDNF- dependent arc
induction could be attributed to oxidative stress. ALCAR was found to rescue the levels of arc in
neurons exposed to Dox and higher expression levels were observed in untreated controls in the
absence of BDNF (Figure 3.10). ALCAR functions indirectly as an antioxidant and primarily
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regulates mitochondrial function through interactions with metabolic components in the
organelle (Zanelli et al., 2005). Perhaps through effects on mitochondria and energy metabolism,
ALCAR could exert its restoring effects on gene expression through the activation of mTORC
signaling (Schieke et al., 2006).
Increased levels of the oxidative damage marker were found in cells both in vivo
(Chapter 2) and in the dissociated hippocampal neuron cultures after chemotherapy. It is likely
that the potential damage to RNA species may be contribute to the reduced expression of arc
protein. Messenger RNA and ribosomal RNA are vulnerable to oxidative damage and is a
hallmark of the aging process and the progression of several neurodegenerative diseases (Kong
and Lin, 2010). Therefore, it is possible that the Dox- induced oxidative damage to rRNA and
other translational components could suppress the overall rates of protein synthesis (Simms and
Zaher, 2016). Alternatively, specific mRNA transcripts could be more susceptible to oxidative
damage. The presence of an oxidized base on mRNA could impact the fidelity of translation
leading to increased levels of truncated proteins (Tanaka et al., 2007). The contribution of these
oxidative modifications to the control of gene expression control in the brain have not been
previously explored in chemotherapy-related cognitive impairment. We propose here that
oxidative damage to nucleic acids can be induced by chemotherapy in the brain leading to a
reduction in the protein content of specific targets. These modifications could therefore play a
role in the pathophysiology of cognitive impairment after treatment.
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Chapter 4.1: Conclusions and Future Directions
The cognitive changes associated with cancer and/or cancer treatments is becoming a
growing concern. Over the last decade, the increase in the number systematic research studies
have been instrumental in our understanding of the various factors that contribute to the
development of CRCI. The use of animal models as experimental tools expands on these clinical
findings and allow for the determination of the independent effects of chemotherapy after
controlling for confounding variables. Additionally, these animal studies facilitate the
exploration of behavioral and dietary interventions for CRCI that could potentially translate into
human clinical trials.
The ovariectomized (OVX) rat is a model for surgically- induced ovarian loss and
menopause. An overwhelming number of studies on cognitive dysfunction in breast cancer
patients address menopausal status and endocrine therapy as contributory factors to CRCI,
considering that hormone imbalance is documented to influence cognition (Greendale et al.,
2011). The findings presented in this dissertation reveal the molecular and behavioral
consequences of systemic AC chemotherapy in a post-menopausal rat model. The conclusions
and limitations to the experiments addressed in this study are outlined in this chapter.
4.1 Chemotherapy induces cognitive dysfunction in rodent models
We find that cyclophosphamide and doxorubicin-treated rats showed significantly
impaired performance on the Y maze spontaneous alternation and the novel object recognition
tasks suggesting a disruption in prefrontal cortex and hippocampal mediated memory function.
We investigated specific behaviors in the animals after treatment, but it may be necessary to
include other cognitive domains that are relevant to the cognitive tasks assessed in clinical
settings (Dumas et al.,2013; Kesler et al., 2017). The rodents used in this study are relatively
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young in age, tumor-free and genetically homogeneous, and thus may not recapitulate all
physiological features observed in cancer patients (Kovalchuck et al., 2017). Additionally, the
ovariectomy performed in both the saline and chemotherapy groups may be responsible for
inducing behavioral and molecular changes in the CNS before the onset of treatment.
Nevertheless, our studies demonstrate that these cytotoxic agents can impair cognitive function
independent of cancer or hormonal status (Salas-Ramirez et al., 2015).
4.2 Altered signal transduction and gene expression is associated with CRCI
A differential activation and expression of the BDNF-TrkB receptor isoforms in the
hippocampus and PFc was found in rats after treatment. There were also alterations in the protein
and/or mRNA expression of several IEGs in the hippocampus of chemotherapy- treated groups.
These proteins are involved in pathways related to synaptic plasticity, learning and memory, and
may be linked to the behavioral changes we observed in the animals. Future studies will be
required to examine a potential cause–effect relationship of these molecular alterations in
relation to cognitive status after treatment. The expression of the IEGs were assessed in tissue
lysates, but it will be necessary to evaluate the subcellular distribution (e.g. nuclear, cytoplasmic,
dendritic) or the cell specific expression of these molecules in order to gain a full understanding
of their functional relevance. In this study, the levels of the IEG products were measured under
relatively basal conditions. However, many of the IEG proteins also function as effector
molecules or transcription factors that are selectively upregulated and activated in response to
synaptic activity (Minatohara et al., 2016). It will be of interest to examine whether
chemotherapy effects the behaviorally/activity -induced pattern of de novo gene expression. The
in vitro model of doxorubicin –induced neurotoxicity sheds some light on the molecular
consequences of chemotherapy. In particular, we show that drug exposure can disrupt
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neurotrophin-evoked signaling and gene expression in isolated neurons. Therefore, impaired
signal transduction may also contribute to neuronal and cognitive dysfunction after
chemotherapy treatment.
4.3 Chemotherapy is associated with the induction of stress responses, inflammation and
oxidative damage
We demonstrate that higher levels of MAPK activities were detected in the hippocampus
and PFc after treatment. The expression of several oxidative stress-related genes and
proinflammatory molecules were also altered in the CNS of these animals. In this study, we
adopted a novel approach to examine the consequences of chemotherapy on nucleic acid
oxidative modifications in the brain. The significantly higher levels of rRNA oxidation could
induce ribosome dysfunction and impair translational processes, which may play a role in the
pathogenesis of CRCI (Simms and Zaher, 2016). It will be necessary to examine the effects of
treatment on the oxidation status of other RNA species (e.g. mRNA, other non-coding RNA) and
to address whether specific gene transcripts are selectively targeted by oxidative damage (Kong
and Lin 2010; Nunomura et al., 2017). Other brain regions should be evaluated in future studies
to clarify how ROS and oxidative stress could interact with the cognitive domains reportedly
vulnerable to chemotherapy treatment.
The cytotoxic effects of direct doxorubicin exposure are also related to the induction of
ROS levels in neurons. We show that drug –mediated oxidative stress is associated with
impaired signal transduction and the expression of the plasticity protein arc/arg3.1, effects that
can be partially reversed by antioxidant supplementation. Additional in vitro electrophysiological
techniques may be necessary to explore the cellular mechanisms that underlie changes in
synaptic plasticity with treatment. Overall, our findings support the postulate that molecular
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changes in response to the physiological challenge induced by systemic chemotherapy contribute
to cognitive deficits.
4.4 Future Directions
Future studies into the mechanisms of CRCI will explore the connection between
oxidative stress and epigenetics (Wang et al.,2015; Pan et al.,2018). Epigenetics are the
processes that involve heritable changes in gene function/expression that do not involve changes
in the DNA sequence. These changes are regulated by mechanisms that include DNA
methylation, histone modifications, miRNA and non-coding RNAs (Banister, 2012). Epigenetic
changes are associated with chemotherapy and other DNA damaging agents, and represent one
of the hallmarks of aging (Cencioni et al. 2013). An increasing number of studies are also
highlighting a role for the alterations in memory processes and cognitive functioning (Day and
Sweatt, 2011). Considering the global impact of oxidative damage on macromolecules such as
proteins and nucleic acids, it is of interest to examine whether oxidative stress and epigenetic
changes contribute to the pathogenesis of cognitive dysfunction after chemotherapy treatment.
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